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1.              Introduction 
 
1.1 dsRNA, siRNA, miRNA and shRNA 
 
1.1.1 dsRNA 
Double-stranded RNA (dsRNA) is RNA with two complementary strands, 
similar to the DNA. dsRNA forms the genetic material of some viruses. In 
eukaryotes, it acts as a trigger to initiate the process of RNA interference 
(RNAi) and presents as an intermediate step in the formation of siRNA (small 
interfering RNAs). Recently, dsRNA has been found to induce gene 
expression at the transcriptional level, a phenomenon named small RNA 
induced gene activation RNAa. Such dsRNA is called small activating RNA 
(saRNA). 
 
1.1.2 siRNA 
Small interfering RNAs (siRNAs), sometimes known as short interfering RNA 
or silencing RNAs, represent a class of 20-25 nucleotide-long 
double-stranded RNA molecules that play a variety of roles in biology. 
 
siRNAs have a well defined structure: a short (usually 21-nt) double-strand of 
RNA (dsRNA) with 2-nt 3 overhangs on either end. Each strand has a 5 
phosphate group and a 3 hydroxyl (-OH) group. This structure is the result of 
processing by Dicer, an enzyme that converts either long dsRNA or hairpin 
RNAs into siRNAs (Baulcombe et al, 1999). 
 
Most notably, siRNAs are involved in the RNA interference (RNAi) pathway 
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where the siRNA interferes with the expression of a specific gene (Tuschl et al, 
2001). In addition to their role in the RNAi pathway, siRNAs also act in 
RNAi-related pathways, as an antiviral mechanism or in shaping the 
chromatin structure of a genome. siRNAs can also be exogenously (artificially) 
introduced into cells by various transfection methods to bring about the 
specific knockdown of a gene of interest. Essentially any gene of which the 
sequence is known can thus be targeted based on sequence complementarity 
with tailored siRNA. This has made siRNA an important tool for gene function 
and drug target validation studies in the post-genomic era. 
 
1.1.3 miRNA 
The vast majority of genomic DNA does not encode protein sequences and 
was considered junk that only contributes to the evolution of genes due to 
recombination events. However, very recently this concept had to be 
completely rewritten. Hundreds of short RNAs have been identified that stem 
from these noncoding regions and many more are likely to exist. These 
microRNAs (miRNAs) are important regulators of gene expression.  
 
In genetics, miRNAs are single-stranded RNA molecules of about 21-23 
nucleotides in length, which regulate gene expression. miRNAs are encoded 
by genes that are transcribed from DNA but not translated into protein 
(non-coding RNA); instead they are processed from primary transcripts known 
as pri-miRNAs to short stem-loop structures called pre-miRNAs and finally to 
function miRNAs. Mature miRNA molecules are partially complementary to 
one or more messenger RNA (mRNA) molecules, and their main function is to 
down-regulate gene expression. 
 
1.1.3.1 Formation and processing of miRNA 
The genes encoding miRNAs are much longer than the processed mature 
miRNA molecule; miRNAs are first transcribed as primary transcripts or 
pri-miRNAs with a cap and poly-A tail and processed to short, 70-nucleotide 
stem-loop structures known as pre-miRNAs in the cell nucleus. This 
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processing is performed in animals by a protein complex known as the 
Microprocessor complex, consisting of the nuclease Drosha and the 
double-stranded RNA binding protein Pasha (Denli et al, 2004). These 
pre-miRNAs are then processed to mature miRNAs in the cytoplasm by 
interaction with the endonuclease Dicer, which also initiates the formation of 
the RNA-induced silencing complex (RISC) (Bernstein et al, 2001). This 
complex is responsible for the gene silencing observed due to miRNA 
expression and RNA interference. The pathway in plants varies slightly due to 
the lack of Drosha homologs; instead, Dicer homologs alone affect several 
processing steps (Kurihara and Watanabe, 2004). 
 
It has been shown that the efficient processing of pre-miRNAs by Drosha 
requires the presence of extended single-stranded RNAs on both 3'- and 
5'-ends of hairpin molecules (Zeng et al, 2005). This study showed that these 
motifs could be of different composition while their defined length is of high 
importance for processing to take place. Findings were confirmed in another 
work by Han et al (2004). Using bioinformatics tools the folding of 321 human 
and 68 fly pri-miRNAs was analysed. 280 human and 55 fly pri-miRNAs were 
selected for further study excluding those molecules where folding showed 
the presence of multiple loops. All human and fly pri-miRNAs contained very 
similar structural regions, which the authors called 'basal segments', 'lower 
stem', 'upper stem' and 'terminal loop'. Based on the encoding position of 
miRNAs, in the 5'-strand (5'-donors) or 3'-strand (3'-donors), thermodynamic 
profiles of pri-miRNAs were determined (Zeng et al, 2005). Subsequent 
experiments showed that Drosha complex cleaves RNA molecules ~2 helical 
turns away from the terminal loop and ~1 turn away from basal segments. In 
most analyzed molecules this region contains unpaired nucleotides and the 
free energy of the duplex is relatively high compared to lower and upper stem 
regions (Zeng and Cullen, 2005). 
Most pre-miRNAs don't have a perfect double-stranded RNA (dsRNA) 
structure topped by a terminal loop. There are few possible explanations for 
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such selectivity. One could be that dsRNAs longer than 21 base pairs activate 
an interferon response and the anti-viral machinery in the cell. Another 
plausible explanation could be that the thermodynamical profile of 
pre-miRNAs determines which strand will be incorporated into the Dicer 
complex. Indeed, the aforementioned study by Han et al. demonstrated very 
clear similarities between pri-miRNAs encoded in respective (5'- or 3'-) 
strands.  
When Dicer cleaves the pre-miRNA stem-loop, two complementary short 
RNA molecules are formed, but only one becomes integrated into the RISC 
complex. This strand is known as the guide strand and is selected by the 
argonaute protein, the catalytically active RNase in the RISC complex, on the 
basis of the stability of the 5' end (Preall et al, 2006). The remaining strand, 
known as the anti-guide or passenger strand is degraded as a RISC complex 
substrate (Gregory et al, 2005). After integration into the active RISC complex, 
miRNAs base pair with their complementary mRNA molecules and induce 
mRNA degradation by argonaute proteins. It is as yet unclear how the 
activated RISC complex locates the mRNA targets in the cell, though it has 
been shown that the process is not coupled to ongoing protein translation 
from the mRNA (Sen et al, 2005).  
 
1.1.3.2 Cellular functions of miRNA 
The miRNAs appear to be important for gene regulation. An individual miRNA 
is complementary to a part of one or more messenger RNAs (mRNAs). 
Animal miRNAs are usually complementary to a site in the 3' UTR whereas 
plant miRNAs are usually complementary to coding regions of mRNAs. The 
annealing of the miRNA to the mRNA then inhibits protein translation, but 
sometimes facilitates cleavage of the mRNA. This is thought to be the primary 
mode of action of plant miRNAs. In such cases, the formation of the 
double-stranded RNA through the binding of the miRNA triggers the 
degradation of the mRNA transcript through a process similar to RNAi, though 
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in other cases it is believed that the miRNA complex blocks the protein 
translation machinery or otherwise prevents protein translation without 
causing the mRNA to be degraded. miRNAs may also target methylation of 
genomic sites which correspond to targeted mRNAs. miRNAs function in 
association with a complement of proteins collectively termed the miRNP 
(micro-ribonucleic protein). 
 
This effect was first described for the worm C. elegans in 1993 (Lee et al., 
1993). As of 2002, miRNAs have been confirmed in various plants and 
animals, including C. elegans, human and the plant Arabidopsis thaliana. 
Genes have been found in bacteria that are similar in the sense that they 
control mRNA abundance or translation by binding a mRNA by base pairing, 
however they are not generally considered to be miRNAs because the Dicer 
enzyme is not involved. 
 
In plants, similar RNA species termed short-interfering RNAs are used to 
prevent the transcription of viral RNA. While this siRNA is double-stranded, 
the mechanism seems to be closely related to that of miRNAs, especially 
taking the hairpin structures into account. siRNAs are also used to regulate 
cellular genes, as miRNAs do. 
 
1.1.4 shRNA 
Short hairpin RNAs (shRNAs) are a sequence of RNAs that makes a tight 
hairpin turn and are transcribed by RNA polymerase Ⅲ. It uses a vector 
introduced into cells and utilizes the U6 promoter to ensure that the shRNA is 
always expressed and can be cleaved by the cellular machinery into siRNA, 
which is then bound to the RISC silencing gene expression via RNAi 
(Brummelkamp et al., 2002; Lee et al., 2002; Miyagishi and Tiara, 2002; 
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Paddison, et al. 2002; Paul et al., 2002; Sui et al., 2002; Cao et al, 2005; 
Harper et al., 2005; McIntyre and Fanning, 2006). In direct comparisons, 
RNAi via shRNA was much more effective than antisense 
oligodeoxynucleotides (ODNs) targeted to the same gene (Miyagashi et al., 
2003) and showed a longer duration of the inhibitory effect on the 
corresponding mRNA level (Bertrand et al., 2002). 
 
Meanwhile, RNA polymerase Ⅲ-based shRNA expression vector systems 
have been established to induce RNAi in mammalian cells (Brummelkamp et 
al., 2002; Lee et al., 2002; Miyagishi and Tiara, 2002; Paul et al., 2002; Yu et 
al., 2002). Although these vectors provide certain advantages over chemically 
synthesized siRNAs, some disadvantages still remain, including transient 
shRNA expression and low transfection efficiency, especially in primary 
non-dividing cells. Because mammals apparently lack mechanisms that 
amplify silencing in worms and plants, siRNA induced gene inactivation 
seems to be transient (Hannon, 2002). To overcome these limitations, shRNA 
delivery systems using lentiviral vectors have been developed. These 
systems produce shRNAs intracellularly and often rely on promoters 
dependent on RNA polymerase Ⅲ, such as U6 (Abbas et al., 2002; Qin et al., 
2003). The U6 promoter efficiently expresses shRNAs which undergo Dicer 
processing into 21-nucleotide duplex dsRNA in mammalian cultured cells and 
RNA polymerase Ⅲ promoters are active in all mammalian tissues (Wall and 
Shi, 2003). One of the advantages of using the lentivirus system over a 
plasmid-based expression system is to maintain the transferred shRNAs 
stably integrated into the host chromosomal DNA without time-consuming 
drug-selection procedures. Another advantage to the lentivirus-mediated 
gene delivery system is its highly efficient transduction ability. This is of 
particular importance for post-mitotic primary non-dividing cells, such as stem 
cells, dendritic cells and neurons (Naldini et al., 1996; Pfeifer et al, 2002; 
Scherr and Eder, 2002; Stewart et al., 2003; Rubinson et al, 2003; Hironori 
Nishitsuji et al., 2004). 
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shRNAs can also be made for use in plants and other systems, and are not 
necessarily driven by a U6 promoter. In plants the traditional promoter for 
strong constitutive expression (in most plant species) is the cauliflower 
mosaic virus 35S promoter (CaMV35S), in which case RNA polymerase Ⅱ is 
used to express the transcript destined to initiate RNAi. 
 
 
1.2 RNA interference 
RNA interference (RNAi) was a term coined by Fire and coworkers to 
describe the inhibition of gene expression by double-stranded RNAs (dsRNAs) 
when introduced into nematode worms (Caenorhabditis elegans). Following 
on from the studies of Guo and Kemphues (1995), who had found that sense 
RNA was as effective as antisense RNA for suppressing gene expression in 
worms, Fire et al. (1998) applied single-stranded antisense RNA and double 
stranded RNA in their experiments. To their surprise, they found that dsRNA 
was more effective in producing interference than was either strand 
individually. After injection into adult C. elegans, single-stranded antisense 
RNA had a modest effect in diminishing specific gene expression, whereas 
double-stranded mixtures caused potent and specific interference.  
 
Today we know that RNAi is a multistep process involving the generation of 
small interfering RNAs (siRNAs) in vivo through the action of the RNase III 
endonuclease Dicer. The resulting 21- to 23-nt siRNAs mediate the 
degradation of their complementary RNA (Shi, 2003).  
 
A major breakthrough in the elucidation of the underlying mechanism was the 
biochemical analysis of RNAi using Drosophila embryo or cell extracts (Tuschl 
et al., 1999; Hammond et al., 2000; Zamore et al., 2000), which led to the 
identification of the dsRNA processing enzyme Dicer (Bernstein et al., 2001a) 
as well as the RNA induced silencing complex, RISC (Hammond et al., 2000), 
which executes RNAi by using the small dsRNA species generated by Dicer 
as guidance molecules to target the homologous, endogenous mRNA for 
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degradation (Elbashir et al., 2001b,c; Zamore et al., 2000). These discoveries 
led to the rapid improvement of RNAi tools, tailored to the needs of the 
various experimental systems, and triggered intense genetic and biochemical 
research into the molecular basis and regulation of RNAi (Hammond et al., 
2001b; Tijsterman et al., 2002). It became clear that RNAi is a highly 
conserved mechanism that functions in many different cellular pathways from 
regulating gene expression to fighting infection and the dangers of mobile 
genetic elements. 
 
1.2.1 Mechanism of RNAi 
The genetic and biochemical analysis of RNAi has led to a model, in which 
RNAi can be divided into two distinct phases: an initiation and an execution 
phase. The initiation phase involves the processing of dsRNA into siRNA. In 
the execution phase, siRNAs are then incorporated into large 
ribonucleoprotein complexes. These effector complexes interfere with gene 
expression by using the small RNA strand to identify their complementary 
mRNA, which becomes cleaved and degraded. In a related pathway, short 
non-coding single stranded RNAs, which are derived from partially 
complementary dsRNA precursor molecules, are used to regulate the 
translation of mRNAs harbouring complementary sequences in their 3UTRs 
(Fig. 1). 
 
1.2.1.1 Initiation phase: dsRNA processing into siRNAs 
The goal of the initiation step of RNAi is the generation of siRNAs from long 
dsRNAs or mature miRNAs from their primary transcripts. This is achieved by 
the action of two families of RNase III-dependent genes, Dicer and Drosha. 
RNase III enzymes fall into three classes (Nicholson, 2003). Class I enzymes, 
found in bacteria and yeast, contain a single RNase III domain joined to a 
dsRBD (dsRNA binding domain proteins). Class II and III enzymes contain 
two RNase III catalytic domains. Class III enzymes are further characterized 
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Fig. 1. Mechanism of RNAi (adopted from Cullen BR., 2004). The processing pathway 
proceeds from transcription through nuclear processing, nuclear export, cytoplasmic 
processing by Dicer and finally to incorporation into RISC. This results in the initial primary 
miRNA transcript (pri-miRNA) being processed to a pre-miRNA and finally to a miRNA duplex 
intermediate, one strand of which then serves as a substrate for RISC incorporation. The 
assembled RISC can then target mRNAs bearing a perfectly complementary target site for 
degradation or can inhibit the translation of an mRNA that contains multiple, partly 
mismatched target sites. Entry points for designed siRNAs are shown at the left of the figure. 
These include synthetic siRNA duplexes and shRNAs, transcribed from expression plasmids, 
which closely mimic pre-miRNAs. Finally, artificial miRNA genes can also be used to express 
novel siRNAs. 
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by a helicase domain and a PAZ (Piwi/Argonaute/Zwille) domain. This last 
domain is also present in Argonaute family proteins, already known to be 
essential for RNAi, which led to the proposal that Class III enzymes are the 
initiator of RNAi (Bass, 2000).  
 
The generation of a siRNA from dsRNA potentially requires four 
endonucleolytic reactions. It has been revealed that Dicer acts as a monomer, 
using two endonucleolytic reactions to generate one new terminus (Zhang et            
al, 2004). This would occur if Dicer binds to an existing terminus and makes a 
cut ~21 nucleotides from the end (Schütze, 2004). If however the enzyme can 
not initiate processing from the end and is forced to cut internally, the reaction 
becomes significantly delayed. Once binding of Dicer occurred and a single 
new terminus is created, further processing occurrs at normal rates, since the 
enzyme now has terminal ends from which to process. 
 
MicroRNAs (miRNAs) are transcribed by RNA polymerase II as long primary 
transcripts (Kim, 2005). The active miRNA species, termed the mature RNA, 
is present in a stemloop structure within the primary transcript. The 
stemloop can be located in an exon or in an intron. For example, the 
miRNAs miR-106b, miR-93, and miR-25 are located within an intron of the 
protein coding gene mcm-7. After transcription, the miRNAs are processed 
from the primary transcript, and the spliced mRNA is exported and translated . 
Sequential processing of the primary transcript by the RNase III enzymes 
Drosha and Dicer liberates the mature RNA. Drosha cleavage releases the 
stemloop, termed the precursor, which is exported from the nucleus in an 
exportin-5/RAN-GTPase-dependent manner. In the cytoplasm, the precursor 
is processed into a siRNA-like structure by Dicer. Drosha generates a 2 nt 3 
overhang terminus on the precursor which is recognized by the PAZ domain 
of Dicer, analogous to the recognition of dsRNA termini. The double stranded 
miRNA is incorporated into RISC in a similar manner as siRNAs. 
 
Drosha is a Class II enzyme. This enzyme assumes a pseudo-dimer catalytic 
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core similar to Dicer (Han et al, 2004). The substrates of Drosha, miRNA 
primary transcripts, are structurally distinct from Dicer substrates. Drosha 
does not process from a dsRNA terminus. Rather, data suggests that 
primarily the stemloop structure is recognized. In particular, the loop size 
appears to be important for recognition (Zeng et al, 2005). In addition, 
unstructured sequences flanking the stemloop are essential for processing 
(Chen et al, 2004; Zeng et al, 2005). It is not evident how Drosha is able to 
recognize these sequences, as they are outside of the dsRNA stem. Possibly 
other unidentified cofactors play a role. Conserved sequence elements have 
been found in flanking regions of C. elegans miRNAs (Ohler et al, 2004). 
 
1.2.1.2 Execution phase: assembly of siRNA containing 
silencing complexes 
Dicer-generated siRNAs are then incorporated into a large multiprotein 
complex, which is involved in various gene-silencing modes, and is called the 
RNA induced silencing complex, or RISC (Hammond et al, 2000; Nykanen et 
al, 2001). Processing of dsRNA and assembly of a functional RISC likely 
occurs in the cytoplasm, as Dicer is a cytosolic enzyme and RISC activity can 
be purified from the cytosol (Billy et al, 2001). R2D2, a Drosophila gene 
related to the C. elegans RNAi gene RDE-4, has been implicated in the 
transfer of siRNAs into the RISC (Liu et al, 2003). Generation of siRNAs from 
dsRNA in Drosophila embryo extracts, unwinding of the siRNA duplex, and 
incorporation into the RISC requires ATP (Nykanen et al, 2001). In contrast, 
human Dicer does not seem to rely on ATP for processing of dsRNA into 
siRNA molecules (Zhang et al., 2002). 
 
Chromatographic purification of RISC nuclease activity from Drosophila cells 
revealed several RISC components. The first identified component was 
Argonaute2 (Ago2) (Hammond et al, 2001). This protein is a member of a 
gene family conserved in most eukaryotic and several prokaryotic genomes. 
The C. elegans homolog, rde-1, was previously identified in a genetic screen 
for RNAi-deficient mutants, reinforcing its connection with RNAi (Tabara et al, 
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1999). Structurally, this protein family is characterized by two domains, the 
PAZ domain and the PIWI domain. Structures for both domains have been 
solved. Additional RISC components with unknown roles in RNAi have also 
been identified. These include the RNA binding protein VIG, the Drosophila 
homolog of the Fragile X protein, dFXR, helicase proteins, and Tudor-SN 
(Ishizuka et al, 2002; Caudy et al, 2003). This last protein has five 
staphylococcal nuclease (SNase) domains and a Tudor domain. 
 
In humans, there are four closely related Argonaute family members, named 
Ago1-4. All four bind siRNAs and miRNAs at similar levels, and are widely 
expressed. Only Ago2, however, is present in a cleavage-competent 
RISC-complex (Meister et al, 2004). Similarly, siRNA-mediated knockdown, 
or targeted knockout, of Ago2 impaired RNAi of a reporter, while knockdown 
of Ago1, 3, 4 had no effect. The crystal structure of an Argonaute family 
member from Pyrococcus furiosus has been revealed (Song et al, 2004). The 
structure displayed an RNaseH fold for the signature PIWI domain. The 
crystal structure of a second archaean argonaute, Archaeoglobus fulgidus 
Piwi (AfPiwi), confirmed the RNaseH fold (Parker et al, 2004). The final 
demonstration that Slicer activity was contained within Ago2 was the 
reconstitution of minimal RISC with bacterially expressed, purified Ago2 and a 
single-stranded siRNA (Rivas et al, 2005).  
 
1.2.2 Therapeutic applications of RNAi 
The therapeutic applications of RNAi are potentially enormous. The genetic 
etiology of many disorders has now been defined and, in some cases, has 
been targeted by RNAi in in vitro and in vivo model systems. Because the 
specificity of RNAi is governed by sequence complementarity between the 
siRNA and the target RNA, the most obvious application would be to treat 
diseases in which genetic polymorphisms within the disease-inducing gene in 
a particular lesion or tumor can be targeted for degradation without affecting 
RNA from wild-type alleles. 
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1.2.2.1 Cancer 
There are two general abnormalities in cancer cells that exhibit a 
dysregulation of the cell cycle resulting in uncontrolled growth and are 
resistant to death as a result of abnormalities in one or more proteins that 
mediate apoptosis (Nam and Parang, 2003). The goals for RNAi approaches 
for cancer therapy are therefore to silence the expression of a cell cycle gene 
and/or an anti-apoptotic gene in the cancer cells thereby stopping tumor 
growth and killing the cancer cells. To selectively eliminate cancer cells 
without damaging normal cells, the RNAi needs to be targeted to a gene 
specifically involved in the growth or survival of the cancer cell, or the siRNAs 
would be selectively delivered into the cancer cells. 
 
The translocation of the Philadelphia chromosome (Ph) generates a fusion 
gene called BCR-ABL. The translation product of this gene creates a 
constitutively active protein tyrosine kinase that induces and maintains 
leukemic transformation in chronic myelogenous leukemia and Ph-positive 
acute lymphoblastic leukemia. The siRNAs specific for the BCR-ABL 
transcript have been shown to silence the oncogenic fusion transcripts without 
affecting expression levels of normal c-ABL and c-BCR transcripts (Scherr et 
al, 2003; Wohlbold et al, 2003).  
 
Pancreatic and colon carcinomas, in which RAS genes are often mutated, 
provide another example for potential RNAi applications. In many cases, the 
RAS oncogenes contain point mutations that differ by a single-base mutation 
from their normal counterparts. The use of retroviral vectors to introduce 
interfering RNAs specific for an oncogenic variant of KRAS (called K-RASV12) 
reduced the level of K-RASV12 transcripts and resulted in a loss of 
anchorage-independent growth and tumorigenicity (Brummelkamp et al, 
2002). Studies of this kind provided proof-of-concept data for RNAi-based 
strategies aiming to reverse tumorigenesis. 
 
1.2.2.2 Infectious diseases 
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The ability of RNAi to inhibit the replication or cellular uptake of viruses and 
other infectious agents has been clearly demonstrated in cell culture studies 
and, therefore, holds promise for the treatment of human patients. The ability 
of HIV-1 to infect cells and replicate can be severely compromised by 
targeting viral genes using siRNAs. Examples include the suppression of 
HIV-1 replication in human cells transfected with siRNA directed against the 
tat and the rev gene (Capodici et al, 2002; Jacque et al, 2002; Lee et al, 
2002a; Novina et al, 2002). Transfection of human cells with siRNAs directed 
against different genes in the poliovirus genome resulted in resistance of the 
cells to infection with poliovirus (Gitlin et al., 2002). The ability of siRNAs 
targeting the gene encoding the death receptor Fas to protect mice from liver 
failure and fibrosis in two models of autoimmune hepatitis was tested by Song 
and colleagues (Song et al., 2003). Intravenous injection of Fas siRNA 
specifically reduced Fas protein levels in the livers of mice during a 10-day 
period. Fas siRNA treatment abrogated hepatocyte necrosis and 
inflammatory infiltration and markedly reduced serum concentrations of 
transaminases demonstrating a clear hepatoprotective effect of the siRNA 
therapy. 
 
1.2.2.3 Neurodegenerative disorders  
RNAi has been proven to be a successful experimental approach to alleviate 
symptoms of diseases in transgenic animal models. For example, in inducible 
mouse models of spinocerebellar ataxia type 1 (SCA1) and Huntington 
disease, the repression of the mutant allele partially alleviates disease 
phenotype. Adeno-associated virus (AAV) expressing shRNA directed 
against transgenic mutated human ataxin and injected into cerebellum 
profoundly improved motor coordination, restored cerebellar morphology, and 
resolved characteristic ataxin-1 inclusions in Purkinje cells of SCA1 mice (Xia 
et al, 2004). Amyotrophic lateral sclerosis (ALS) is another devastating 
neurodegenerative disease, which is generally sporadic but in a small number 
of cases is caused by the expression of a mutated form of Cu/Zn superoxide 
dismutase (SOD1). Although the mutant SOD1 is toxic, the wild-type SOD1 
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performs important functions. Therefore, a selective down-regulation of the 
mutated isoform would be desirable. A specific siRNA covering the sequence 
containing the point mutation has been tested in experimental models of SOD 
dysfunction and showed that such an approach is feasable (Ding et al, 2003). 
However, there are multiple forms of mutant SOD1 and not all mutant types 
have been selectively inhibited by RNAi. An alternative approach has been 
designed in which RNAi is used to inhibit both wild-type together with the 
mutated form of SOD1. The wild-type SOD1 function is then replaced by an 
engineered SOD1 gene resistant to the RNAi (Xia et al, 2005). 
 
1.2.2.4 Drawbacks of RNAi therapeutics 
Delivery is probably the single biggest obstacle to the development of 
RNAi-based therapeutic agents. Trigger RNAs (dsRNAs from which siRNAs 
are derived by the action of Dicer) can be expressed from vectors or delivered 
as artificial siRNAs. A variety of strategies to express interfering RNAs with 
the use of plasmid and virus vector-based cassettes have been explored (Li et 
al, 2002; Dykxhoorn et al, 2003). Well-documented hazards of inserting 
foreign vector sequences into chromosomal DNA include insertional 
activation and inactivation of cellular genes. Direct (intravenous) 
administration of siRNAs would require siRNAs that are modified to be 
resistant to nucleases and perhaps conjugated with a ligand to target the 
siRNA to specific tissues. In mice, intravenous introduction of Fas siRNAs 
leads to specific silencing of Fas mRNA in the liver (Song et al, 2003), so in 
principle, unmodified siRNAs can be taken up by the liver and perhaps other 
tissues. It is not clear, however, whether there are selective tissue sites for the 
uptake of siRNAs and whether the lymphoid system or the brain, for instance, 
is accessible by this route. Furthermore, the silencing effect of siRNAs is 
short-lived, because the siRNAs eventually decay within the cell. In addition to 
the danger of using vectors that integrate into the genome, the expression or 
injection of siRNAs may also have unwanted biologic side effects. 
Researchers are continually finding new cellular processes in which RNAi is 
involved. Therefore, a stoichiometric excess of a virus-specific siRNA, for 
 
1. Introduction                                                                    
 
 
16
example, could saturate RNAi and interrupt the pathways normal functions in 
the cell. Interferons, which form part of the hosts defense against viral 
infection, are activated by long dsRNA (more than 500 bp). It is now apparent 
that siRNAs (Sledz et al, 2003) as well as shRNAs expressed from DNA 
vectors (Bridge et al, 2003) can trigger the activation of interferons. However, 
there is no evidence that the activation of interferons by short RNAs 
influences the degree or specificity of RNA silencing. In addition, these effects 
have to be reconciled with the manufacturing in cells of many thousands of 
copies of pre-miRNAs (Lagos et al, 2001) that do not appear to activate 
interferons. 
 
 
1.3 Transfection 
Transfection describes the introduction of foreign DNA into eukaryotic cells. 
Transfection typically involves opening transient holes or gates in the cell 
plasma membrane, to allow the uptake of extracellular molecules, typically 
supercoiled plasmid DNA, but also siRNA, among others. Cells that have 
been manipulated to accept foreign DNA (cells with holes) are called 
competent cells.  
 
The primary challenge for gene transfection is to develop a method that 
delivers a gene (transgene) to selected cells where proper gene expression 
can be achieved. An ideal gene delivery method needs to meet 3 major 
criteria: (1) it should protect the transgene against degradation by nucleases 
in intercellular matrices, (2) it should bring the transgene across the plasma 
membrane and into the nucleus of target cells, and (3) it should have no 
detrimental effects (Gao et al, 2007). 
 
Viral vectors are able to mediate gene transfer with high efficiency and the 
possibility of long-term gene expression, and satisfy 2 out of 3 criteria. The 
acute immune response, immunogenicity, and insertion mutagenesis have 
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raised serious safety concerns about some commonly used viral vectors. The 
limitation in the size of the transgene that recombinant viruses can carry and 
issues related to the production of viral vectors present additional practical 
challenges. Methods of nonviral gene delivery have also been explored using 
physical (carrier-free gene delivery) and chemical approaches (synthetic 
vector-based gene delivery). Physical approaches, including needle injection 
(Wolff et al, 1990), electroporation (Heller et al, 2005), gene gun (Yang et al, 
1990; Yang and Sun, 1995), ultrasound (Lawrie et al, 2000), and 
hydrodynamic delivery (Liu et al, 1999; Zhang et al, 1999), employ a physical 
force that permeates the cell membrane and facilitates intracellular gene 
transfer. The chemical approaches (Mahato and Kim, 2002; Liu et al, 2003; 
Neu et al, 2005) use synthetic or naturally occurring compounds as carriers to 
deliver the transgene into cells. Although significant progress has been made 
in the basic science and applications of various nonviral gene delivery 
systems, the majority of nonviral approaches are still much less efficient than 
viral vectors, especially for in vivo gene delivery. 
 
1.3.1 Transfection by needle injection of naked DNA 
Simple injection of plasmid DNA directly into a tissue without additional help 
from either a chemical agent or a physical force is able to transfect cells. Local 
injection of plasmid DNA into the muscle (Wolff et al, 1990), liver (Zhang et al, 
1997), skin (Choate and Khavari, 1997), or airway instillation into the lungs 
(Meyer et al, 1995), lead to a low-level of gene expression. Specific or 
nonspecific receptors on the cell surface that bind and internalize DNA have 
been implicated as a mechanism. Nevertheless, gene transfer with naked 
DNA is attractive to many researchers because of its simplicity and lack of 
toxicity. However, a broad application of naked DNAmediated gene transfer 
to gene therapy may not be conceivable because DNA, being large in size 
and highly hydrophilic, is efficiently kept out of the cells in a whole animal by 
several physical barriers. These include the blood endothelium, the interstitial 
matrices, the mucus lining and specialized ciliate/tight junction of epithelial 
cells, and the plasma membrane of all cells. In addition, DNA degradation by 
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intra- and extracellular nuclease activities further reduces the chance that 
DNA entering nuclei will be intact and functional. 
 
1.3.2 Transfection by physical methods 
Physical approaches have been explored for transfection into cells in vitro and 
in vivo. Physical approaches induce transient injuries or defects on cell 
membranes, so that DNA can enter the cells by diffusion. Gene delivery 
employing mechanical (particle bombardment or gene gun), electric 
(electroporation), ultrasonic, hydrodynamic (hydrodynamic gene transfer), or 
laser-based energy has been explored in recent years. 
 
1.3.2.1 Transfection by gene gun 
Particle bombardment through a gene gun is an ideal method for transfection 
of skin, mucosa, or surgically exposed tissues within a confined area (Yang et 
al, 1990). DNA is deposited on the surface of gold particles, which are then 
accelerated by pressurized gas and expelled onto cells or a tissue. The 
momentum allows the gold particles to penetrate a few millimeters deep into a 
tissue and to release DNA into cells on the path. Such a simple and effective 
method of gene delivery is expected to have important applications as an 
effective tool for DNA based immunization. Further improvements could 
include chemical modification of the surface of the gold particles to allow 
higher capacity and better consistency for DNA coating, and fine-tuning of the 
expelling force for precise control of DNA deposition into cells in various 
tissues.  
 
1.3.2.2 Transfection by electroporation 
Electroporation is a versatile method that has been extensively tested in many 
types of tissues in vivo (Heller et al, 2005), among which skin and muscles are 
the most extensively investigated, although the system should work in any 
tissues into which a pair of electrodes can be inserted. Gene transfer by 
electroporation showed less variation in efficiency across species than did 
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direct DNA injection. The amount of DNA and how well the injected plasmid 
DNA distributes within the treated tissue prior to electroporation appear to 
have an important impact on transfection efficiency. 
 
Several major drawbacks exist for in vivo application of electroporation. First, 
it has a limited effective range of ~1cm between the electrodes, which makes 
it difficult to transfect cells in a large area of tissues. Second, a surgical 
procedure is required to place the electrodes deep into the internal organs. 
Third, high voltage applied to tissues can result in irreversible tissue damage 
as a result of thermal heating (Durieux et al, 2004). Ca2+ influx due to 
disruption of cell membranes may induce tissue damage because of 
Ca2+-mediated protease activation (Gissel and Clausen, 2001). The possibility 
that the high voltage applied to cells could affect the stability of genomic DNA 
is an additional safety concern. However, some of these concerns may be 
resolvable by optimizing the design of electrodes, their spatial arrangement, 
the field strength, and the duration and frequency of electric pulses. 
 
1.3.2.3 Ultrasound-facilitated transfection 
The discovery that ultrasound can facilitate gene transfer at cellular (Kim et al, 
1996) and tissue levels (Liang et al, 2004) expands the methodology of gene 
transfer by physical methods. A 10- to 20-fold enhancement of reporter gene 
expression over that of naked DNA has been achieved. Unlike electroporation, 
which moves DNA along the electric field, ultrasound creates membrane 
pores and facilitates intracellular gene transfer through passive diffusion of 
DNA across the membrane pores (Koch et al, 2000). The transfection 
efficiency of this system is determined by several factors, including the 
frequency, the output strength of the ultrasound applied, the duration of 
ultrasound treatment (Huber et al, 1999), and the amount of plasmid DNA 
used.  
 
Consequently, the size and local concentration of plasmid DNA play an 
important role in determining the transfection efficiency. Efforts to reduce DNA 
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size for gene transfer by methods of standard molecular biology or through 
proper formulation could result in further improvement. Interestingly, 
significant enhancement has been reported in cell culture and in vivo when 
complexes of DNA and cationic lipids have been used (Anwer et al, 2000). 
Since ultrasound can penetrate soft tissue and be applied to a specific area, it 
could become an ideal method for noninvasive gene transfer into cells of the 
internal organs. Evidence supporting this possibility has been presented: in 
one study, plasmid DNA was co-administered with a contrast agent to blood 
circulation, and this was followed by ultrasound treatment of a selected tissue 
(Unger et al, 2001). So far, the major problem for ultrasound-facilitated gene 
delivery is low gene delivery efficiency. 
 
1.3.2.4 Hydrodynamic transfection 
Hydrodynamic gene delivery is a simple method that introduces naked 
plasmid DNA into cells in highly perfused internal organs, such as the liver, 
with an impressive efficiency (Liu et al, 1999). This simple, reproducible, and 
highly efficient method for gene delivery has been used to express proteins of 
therapeutic value such as hemophilia factors (Miao et al, 2003), alpha-1 
antitrypsin (Alino et al, 2003), cytokines (Jiang et al, 2001), hepatic growth 
factors (Yang et al, 2001), and erythropoietin (Maruyama et al, 2004) in 
mouse and rat models. Depending on the plasmid construct and the 
regulatory elements driving expression of the transgene, the level of gene 
expression in some cases has reached or exceeded the physiological level. 
 
1.3.3 Transfection by chemical methods 
By far the most frequently studied strategy for nonviral gene delivery is the 
formulation of DNA into condensed particles by using cationic lipids or 
cationic polymers. The DNA containing particles are subsequently taken up 
by cells via endocytosis, macropinocytosis, or phagocytosis in the form of 
intracellular vesicles, from which a small fraction of the DNA is released into 
the cytoplasm and migrates into the nucleus, where transgene expression 
takes place. 
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1.3.3.1 Cationic lipid-mediated transfection 
Since 1987, it was first reported that a double chain monovalent quaternary 
ammonium lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium 
chloride, effectively binds and delivers DNA to cultured cells (Felgner et al, 
1987), hundreds of new cationic lipids have been developed. These lipids 
differ by the number of charges in their hydrophilic head group and by the 
detailed structure of their hydrophobic moiety. Although some cationic lipids 
alone exhibit good transfection activity, they are often formulated with a 
noncharged phospholipid or cholesterol as a helper lipid to form liposomes. 
Upon mixing with cationic liposomes, plasmid DNA is condensed into small 
quasi-stable particles called lipoplexes. DNA in lipoplexes is well protected 
from nuclease degradation. Lipoplexes are able to trigger cellular uptake and 
facilitate the release of DNA from the intracellular vesicles before reaching 
destructive lysosomal compartments. 
 
Most of our understanding of lipid-mediated gene delivery derives from 
characterization work on lipoplexes prepared in low-salt solution and 
transfection tests on cells in the absence of interfering substances such as 
serum. Under these conditions, the transfection efficiency of lipoplexes is 
affected by (1) the chemical structure of the cationic lipid, (2) the charge ratio 
between the cationic lipid and the DNA, (3) the structure and proportion of the 
helper lipid in the complexes, (4) the size and structure of the liposomes, (5) 
the total amount of the lipoplexes applied, and (6) the cell type. The first 4 
factors determine the structure, charge property, and transfection activity of 
the lipoplexes. The remaining 2 define the overall toxicity to the treated cells, 
and the susceptibility of the cells to a particular lipid-based transfection 
reagent. The chemical structure of the cationic lipid has a major impact on the 
transfection efficiency. In general, multivalent lipids with long and unsaturated 
hydrocarbon chains tend to be more efficient than monovalent cationic lipids 
with the same hydrophobic chains. Transfection typically requires that the 
cationic lipid be in slight excess over DNA such that the lipoplexes have net 
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positive charges on the surface. Spontaneous lipid mixing in endosomes 
becomes more profound when a non-bilayer-forming lipid such as 
dioleoylphosphatidylethanolamine (DOPE) is used as the helper lipid, rather 
than a bilayer-forming lipid, dioleoylphosphatidylcholine. Inclusion of DOPE is 
believed to increase membrane fluidity and facilitate lipid exchange and 
membrane fusion between lipoplexes and the endosomal membrane. 
 
Lipoplexes form spontaneously when cationic liposomes are mixed with DNA. 
The process involves an initial rapid association of polycationic liposomes and 
polyanionic DNA through electrostatic interaction, followed by a slower lipid 
rearrangement process (Pedroso et al, 2001). The structure of lipoplexes is 
influenced by multiple factors, including the charge ratio, the concentration of 
individual lipids and DNA, the structure of the cationic lipid and the helper lipid, 
the physical aggregation state of the lipids (multilamellar or unilamellar 
liposomes, or micelles), the salt concentration, and the method of preparation. 
Lipoplexes come in various forms, including fully condensed lipid/DNA 
complexes, partially condensed lipid/DNA complexes, DNA sandwiched 
between cationic lipid bilayers, lipid-coated DNA arranged in a hexagonal 
lattice, or partially condensed DNA surrounded by a lipid bilayer (Lin et al, 
2003). The simplest way to prepare lipoplexes is to mix diluted solutions of 
plasmid DNA and preformed liposomes. The resulting lipoplexes are 
generally heterogeneous in size and morphology. The heterogeneity is 
primarily due to the relatively large sizes of DNA and liposomes, and the 
multivariant nature of the interaction between the DNA and liposomes. 
Alternative methods involving forms of lipid assembly other than liposomes 
have been designed to overcome these problems. For example, direct 
addition of DNA solution to a dried film of cationic lipid and DOPE promotes 
entrapment of DNA within multilamellar liposomes, rather than sandwiching of 
DNA between liposomes. 
 
Toxicity related to gene transfer by lipoplexes has been observed. Acute 
inflammation reactions have been reported in animals treated with airway 
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instillation or intravenous injection of lipoplexes. Detailed toxicological studies 
on one of the Genzyme Lipid formulations, GL-67/DOPE, revealed that the 
cationic lipid contributes significantly to the toxicity observed (Ruiz et al, 2001). 
Similar toxic effects are also noticeable in systemic gene delivery via the tail 
vein with other types of cationic lipids. Symptoms include acute pulmonary 
hypotension, induction of inflammatory cytokines, tissue infiltration of 
neutrophils in lungs, decrease in white cell counts, and in some cases tissue 
injury in liver and spleen (Yew and Scheule, 2005). In humans, various 
degrees of adverse inflammatory reactions, including flu like symptoms with 
fever and airway inflammation, were noted among subjects who received 
aerosolized GL67 liposomes alone or lipoplexes. These early clinical data 
suggested that these lipoplexes formulations are inadequate for use in 
humans. 
 
1.3.3.2 Transfection mediated by cationic polymer 
Synthetic and naturally occurring cationic polymers constitute another 
category of DNA carriers that have been used widely for gene delivery. Over 
the years, a significant number of cationic polymers in linear or branched 
configuration have been explored as carriers for in vitro and in vivo gene 
delivery. These include polyethylenimine (PEI) (Chemin et al, 1998), 
polyamidoamine (Rudolph et al, 2000) and polypropylamine dendrimers 
(Schatzlein et al, 2005), polyallylamine, cationic dextran (Hosseinkhaini et al, 
2004), chitosan, cationic proteins (polylysine, protamine, and histones), and 
cationic peptides (Park et al, 2003). Although most cationic polymers share 
the function of condensing DNA into small particles and facilitating cellular 
uptake via endocytosis through charge-charge interaction with anionic sites 
on cell surfaces, their transfection activity and toxicity differ dramatically. One 
drawback in the use of PEI as a transfection reagent relates to its 
nonbiodegradable nature (Fischer et al, 2003). 
 
1.3.3.3 Transfection by lipid-polymer hybrid system 
The reported lipid-polymer hybrid systems include DNA precondensed with 
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polycations, then coated with either cationic liposomes, anionic liposomes, or 
amphiphilic polymers with or without helper lipids (Lee et al, 2006). 
 
When anionic, DOPE-rich liposomes are added to DNA-polycation complexes, 
an extensive reorganization of the lipid membranes takes place following the 
initial contact, resulting in lipid-polymer-DNA complexes with anionic lipid 
coatings. This strategy overcomes the surface charge issue associated with 
cationic lipid-polymer-DNA complexes. The cytotoxicity of the complexes is 
reduced, making the receptor-mediated targeting possible without 
interference of nonspecific charge-charge interaction. 
 
 
1.4 293FT cell lines 
Human Embryonic Kidney cells, also known as HEK cells, HEK 293 or just 
293 cells, are a cell line originally derived, as their name indicates, from 
embryonic human kidney. HEK cells are very easy to grow and transfect very 
readily and so are widely-used in cell biology research. They are also used by 
biotechnology industry to produce therapeutic proteins and viruses for gene 
therapy. 
 
1.4.1 Origins of 293 cells 
293 cells were generated by transformation of cultures of normal human 
embryonic kidney cells with sheared adenovirus 5 DNA in the laboratory of 
Alex Van der Eb in Leiden, Holland in the early 1970s. They are called HEK 
for human embryonic kidney, while the number 293 roots from numbering of 
experiments 
In 1977, Frank Graham and coworkers at McMaster University successfully 
transformed primary human embryo kidney (HEK) cells with DNA from human 
adenovirus type 5 (HAd5), using a calcium phosphate precipitation technique. 
The viral DNA was prepared by repeatedly forcing a solution of it through a 22 
gauge needle, which effectively sheared it into small fragments, later to be 
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incorporated by the HEK cells. Two of 8 studies, each averaging 20 HEK 
cultures, produced successfully transformed HEK cells. In these two 
experiments, after one month of exposure to the viral DNA fragments, a single 
morphologically transformed colony appeared in one culture (Graham et al, 
1977).  
Isolation of the transformed colonies proved difficult. After approximately 75 
days, however, a few morphologically transformed cells were observed. 
These were selected by reducing the serum content of the culture from 10% 
to 2% for several weeks. Once the transformed cells were established, at 
about passage 6, the serum content was returned to 10%. Then followed a 
crisis phase, which lasted over 3 months, during which the cells growth rate 
declined substantially. This phase continued until passage 16 when a sharp 
decrease in population doubling time occurred. This phenomenon also 
occurred in sublines that had been frozen at passage 6. Following the 
establishment of the HEK 293 line, cells were maintained in Eagle medium 
supplemented with 10% calf serum and tryptose phosphate broth, and have 
been subcultured for over 100 passages.  
The process of transformation using sheared HAd5 DNA makes the HEK 293 
line very sensitive to human adenovirus, and permissive to adenovirus DNA. 
Adenoviruses which have traditionally been difficult to cultivate and assay 
(e.g., human Ads 40 and 41) are more readily cultivated using HEK 293 cells. 
This high susceptibility is probably due to the fact that HEK 293 cells 
constitutively express HAd5-specific E1 proteins.  
Subsequent analysis has shown that the transformation was brought about by 
an insert consisting of -4.5 kilo bases from the left arm of the viral genome, 
which became incorporated into human chromosome 19 (Louis et al, 1997). 
 
For many years it was assumed that HEK 293 cells were generated by 
transformation of either a fibroblastic, endothelial or epithelial cell all of which 
are abundant in kidney. However the fact that the cells originated from 
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cultured kidney cells does not clearly indicate the exact cellular origin of the 
HEK 293, as embryonic kidney cultures may contain small numbers of almost 
all cell types of the body. In fact Graham and coworkers more recently 
provided evidence that HEK 293 cells and several other human cell lines 
generated by adenovirus transformation of human embryonic kidney cells 
have many properties of immature neurons, suggesting that the adenovirus 
was taken up and transformed a neuronal lineage cell in the original kidney 
culture (Shaw et al, 2002). 
 
1.4.2 Applications of 293 cells 
As an experimentally transformed cell line, HEK cells are not a particularly 
good model for normal cells, cancer cells, or any other kind of cell that is a 
fundamental object of research. However, they are extremely easy to work 
with, being straightforward to culture and to transfect, and so can be used in 
experiments in which the behaviour of the cell itself is not of interest. Typically, 
these experiments involve transfection in a gene (or combination of genes) of 
interest, and then analyzing the expressed protein; essentially, the cell is used 
simply as a test tube with a membrane. The widespread use of this cell line is 
due to its extreme transfectability by the calcium phosphate method, 
achieving efficiencies approaching 100% as determined by FACS using a 2 x 
PBS buffer. A lower efficiency might be achievable with an HBS buffer.  
 
An important variant of this cell line is the 293T cell line that contains, in 
addition, the SV40 large T antigen, that allows for episomal replication of 
transfected plasmids containing the SV40 origin of replication. This allows for 
amplification of transfected plasmids and extended temporal expression of 
the desired gene products. Note that any similarly domesticated cell line can 
be used for this fort of work; Hela, COS and Chinese Hamster Ovary cell are 
common alternatives. Examples of such experiments include: A study of the 
effects of drug on sodium channels; testing of an inducible RNAi system; 
testing of an isoform-selective protein kinase C agonist; investigation of the 
interaction between two proteins; analysis of a nuclear export signal in a 
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protein (He et al, 1998). 
 
A more specific use of HEK cells is in the propagation of adenoviral vectors. 
Viruses offer an extremely efficient means of delivering genes into cells, since 
this is what they have evolved to do, and are thus of great use as 
experimental tools. However, as pathogens, they also present a degree of 
danger to the experimenter. This danger can be avoided by the use of viruses 
which lack key genes, and which are thus unable to replicate after entering a 
cell. In order to propagate such viral vectors, a cell line that expresses the 
missing genes is required. Since HEK cells express a number of adenoviral 
genes, they can be used to propagate adenoviral vectors in which these 
genes (typically, E1 and E3) are deleted, such as AdEasy. Another application 
of 293, especially 293T, cells is commonly used for the production of lentiviral 
and retroviral vectors. Various retroviral and lentiviral packaging cell lines are 
based on these cells. 
 
 
1.5 The aim of this study 
A major problem of the current discussion of osteoporosis arises from the fact 
that the age-related increase of adipose tissues in bone marrow and the 
simultaneous decrease of osteoblasts may contribute to bone-associated 
diseases like osteoporosis and osteopenia. Besides the possibility of a 
decreased capability of human mesenchymal stem cells (hMSCs), the 
multipotential cells that can differentiate into osteoblasts and adipocytes, to 
differentiate into osteoblasts, transdifferentiation of committed osteoblasts into 
adipocytes could at least partly account for the age-related shift towards 
adipogenic degeneration. In this process, we want to know which gene or 
genes may contribute to the age-related expansion of adipose tissue in 
human bone marrow. 
 
In our laboratory, a cell culture system of human mesenchymal stem cells was 
established that allows not only for osteogenic and adipogenic differentiation 
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but also for transdifferentiation of committed precursors and/or differentiated 
cells between both cell lineages (Schilling et al, 2007a). Comparing 
transdifferentiated adipocytes with committed osteoblasts and vice versa by 
microarray analyses revealed a large number of regulated transcripts, many 
of them associated with signal transduction, metabolism, and transcription but 
mostly distinct from established inducing factors of normal adipogenic and 
osteogenic differentiation, respectively (Schilling et al., 2007a and 2007b). 
Some of selected genes were analyzed by RT-PCR which comfirmed the data 
of the microarray analyses.  
 
Furthermore, it was noticed that mRNA species that are regulated during the 
initiation of transdifferentiation could represent possible control factors for the 
transdifferentiation process. Microarray analyses comparing 
transdifferentiated human mesenchymal stem cells with normally 
differentiated human mesenchymal stem cells exhibited large numbers of 
reproducibly regulated genes for both, adipogenic and osteogenic 
transdifferentiation. In order to evaluate the relevance of individual genes, our 
laboratory designed a scoring scheme to rank genes according to 
reproducibility, regulation level, and reciprocity between the different 
transdifferentiation directions. Therefore, members of several signaling 
pathways like FGF, IGF, and Wnt signaling showed explicitly differential and 
reciprocal expression patterns. Additional bioinformatic analyses of 
microarray data allowed us to identify potential key factors associated with 
transdifferentiation of adipocytes and osteoblasts, respectively (Schilling et al, 
2007b). 
 
In general, the aim of this study was to: (1) develop a strategy of work (2) 
select gene products to be targeted by shRNA; (3) select shRNA clones; (4) 
establish PCR for targeted genes; (5) perform shRNA knockdown approach; 
(6) analyze the silencing effect by RT-PCR. 
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2.                  Materials 
 
2.1 shRNA bacterial glycerol stocks 
 
 
Fig. 2. Map for the pLKO.1 lentiviral vector. It derives from pRRLSIN.cPPT.PGK/GFP/WRPE 
and contains elements for efficient viral packaging and shRNA expression. These include Ψ, 
the lentiviral packaging site; RRE, the Rev-responsive element; cPPT. RSV/5'LTR is a hybrid 
of the Rous Sarcoma virus promoter and the HIV 5'LTR. SIN 3'LTR is the HIV 3'LTR with a 
self-inactivating U3 deletion. Expression of the shRNA is driven by the human U6 promoter 
(hU6). The lentiviral vector also contains the mammalian selection marker puromycin 
resistance gene (PAC) under the control of the PGK promoter as a mammalian selection 
marker. pUCori is the bacterial origin of replication of the plasmid, F1 ori is the single-stranded 
phage F1 origin of replication, and AmpR is the ampicillin resistance gene.  
 
shRNA bacterial glycerol stocks were purchased from SIGMA (Munich, 
Germany) and stored in a -80℃ refrigerator. Each shRNA clone is constructed 
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within the lentivirus plasmid vector pLKO.1-Puro (Stewart et al, 2003; Moffat 
et al, 2006; Root et al, 2006) followed by transformation into Escherichia coli. 
The pLKO.1-Puro vector backbone (Fig. 2), as a self-inactivating lentiviral 
vector, derives from pRRLSIN.cPPT.PGK/GFP/WRPE and contains elements 
for efficient viral packaging and shRNA expression. 
 
 
2.2 Cell line 
The human embryonic kidney 293FT (HEK293FT) cell line was purchased 
from Invitrogen (Karlsruhe, Germany) and was stored in liquid nitrogen. 
Cells were thawed in prewarmed, complete medium, which was replaced 
every 2-3 days and consisted of DMEM (high glucose) supplemented with 
2mM L-glutamine, 10％ heat inactivated FBS, 1U/ml penicillin, 100µg/ml 
streptomycin, 0.1mM MEM non-essential amino acids, according to 
manufacturers instructions. At above 80% confluence, cells were subcultured 
after exposure to trypsin/EDTA. Viability and cell density was determined by 
trypan blue stain (0.4%). The splitting ratio was 1:10. 
 
 
2.3 Chemicals 
Yeast extract                     Sigma Aldrich GmbH, Munich, Germany 
Tryptone                         Sigma Aldrich GmbH, Munich, Germany 
NaCl                            Sigma Aldrich GmbH, Munich, Germany 
Agarose                         Sigma Aldrich GmbH, Munich, Germany 
NaOH                           Sigma Aldrich GmbH, Munich, Germany 
Ampicillin                                        PAA, Cölbe, Germany  
NaAc anhydrate                  Sigma Aldrich GmbH, Munich, Germany 
100% Ethanol                             AppliChem, GmbH, Germany 
HPLC-H2O                                AppliChem, GmbH, Germany 
Boric acid                        Sigma Aldrich GmbH, Munich, Germany 
EDTA                                     AppliChem, GmbH, Germany 
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Glycerol (absolute)                         AppliChem, GmbH, Germany 
Bromophenol blue                 Sigma Aldrich GmbH, Munich, Germany 
Xylene cyanole                   Sigma Aldrich GmbH, Munich, Germany 
 
 
2.4 Experimental Kits 
NucleoSpin® Plasmid Mini Kit                           Düren, Germany 
NucleoSpin® Plasmid Midi Kit                           Düren, Germany 
Big Dye Terminator v1.1 Cycle Sequencing Kit         Applied Biosystems, 
Darmstadt, Germany 
NucleoSEQ Kit                                        Düren, Germany 
HiSpeed Plasmid Midi and Maxi Kit               Qiagen, Hilden, Germany 
NucleoSpin® RNA Ⅱ Mini Kit                            Düren, Germany 
TurboGFP vector                  Sigma Aldrich GmbH, Munich, Germany 
PECLAB Kit                     PECLAB Biotechnology GmbH, Germany 
 
 
2.5 Reagents 
Template Suppression Reagent (TSR)       Applied Biosystems, Darmstadt, 
Germany 
DMEM (high glucose)                             PAA, Cölbe, Germany 
FBS                                        Gibco, Karlsruhe, Germany 
L-glutamine                                      PAA, Cölbe, Germany 
Penicillin/streptomycin                             PAA, Cölbe, Germany 
MEM non-essential amino acids (NEAA)             PAA, Cölbe, Germany 
Trypan blue stain (0.4%)           Sigma Aldrich GmbH, Munich, Germany 
Trypsin/EDTA                                     PAA, Cölbe, Germany 
Lipofectamine 2000                     InvitrogenTM, Karlsruhe, Germany 
Random hexamers                       Bioline, Luckenwalde, Germany 
β- mercaptoethanol                        AppliChem, GmbH, Germany 
10x NH4 buffer                           Bioline, Luckenwalde, Germany 
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dNTPs                                  Bioline, Luckenwalde, Germany 
Taq-polymerase (5000U/ml)               Bioline, Luckenwalde, Germany 
50mM MgCl2                             Bioline, Luckenwalde, Germany 
5x reaction buffer for cDNA synthesis       Bioline, Luckenwalde, Germany 
BioScript reverse transcriptase (200U/µl)    Bioline, Luckenwalde, Germany 
10% SDS                        Sigma Aldrich GmbH, Munich, Germany 
 
3M Na-Acetate (store at room temperature) 
49.22g NaAc anhydrate 
Dissolve to 200ml distilled H2O. 
Adjust pH to 4.3 with 1N NaOH. 
 
Luria-Bertani (LB) Ampicillin liquid medium (store at 4℃) 
Dissolve the following in 800ml distilled H2O: 
10g tryptone 
5g yeast extract 
10g NaCl 
Adjust the pH to 7.0 with 1N NaOH. 
Adjust the volume to 1000ml with distilled H2O. 
Sterilize by autoclaving. 
Add 1µl ampicillin per 1ml LB medium. 
 
Luria-Bertani (LB) Ampicillin solid medium (store at 4℃) 
Dissolve the following in 800ml distilled H2O: 
10g tryptone 
5g yeast extract 
10g NaCl 
15g agarose 
Adjust the pH to 7.0 with 1N NaOH. 
Adjust the volume to 1000ml with distilled H2O. 
Sterilize by autoclaving. 
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Add 1µl ampicillin per 1ml LB medium. 
Transfer medium to plate. 
 
293FT cell culture medium: 
DMEM (high glucose)                             PAA, Cölbe, Germany 
10% FBS                                   Gibco, Karlsruhe, Germany 
0.1mM MEM non-essential amino acids (NEAA)       PAA, Cölbe, Germany 
6mM L-glutamine                                 PAA, Cölbe, Germany 
1% Penicillin/streptomycin                         PAA, Cölbe, Germany 
 
10x TBE buffer (store at room temperature): 
Dissolve the following in 800ml distilled H2O: 
108g Tris 
55g Boric acid 
9.05g EDTA 
Adjust the pH to 8.3 with 1N NaOH. 
Adjust the volume to 1000ml with distilled H2O. 
Sterilize by autoclaving. 
 
0.5x TBE buffer (store at room temperature):  
Dilute 10x TBE buffer 20-fold. 
 
10ml 10x loading dye (store at 4℃): 
Dissolve the following in 4ml distilled H2O: 
3ml glycerol (absolute) 
2ml 0.5M EDTA pH 8.0 
1ml 10% SDS 
5mg bromophenol blue 
5mg xylene cyanole 
 
100bp DNA-ladder (100-3000bp)/ 1kb DNA-ladder (250-10000bp) 
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(store at -20℃): 
100µl 100bp/ 1kb DNA-ladder Plus 
100µl 6x loading buffer (from PECLAB Kit) 
400µl 50nM EDTA 
Adjust pH to 8.0 with 1N NaOH. 
 
PCR master mix (1 reaction): 
HPLC- H2O 21.9µl                          AppliChem, GmbH, Germany 
10x NH4 Buffer 3µl                        Bioline, Luckenwalde, Germany 
dNTPs (10mM) 1µl                       Bioline, Luckenwalde, Germany 
50mM MgCl2 1µl                         Bioline, Luckenwalde, Germany 
Taq-polymerase (5000U/ml) 0.1µl          Bioline, Luckenwalde, Germany 
Primer forward (5pmol/µl) 1µl                     Operon, Köln, Germany 
Primer reverse (5pmol/µl) 1µl                     Operon, Köln, Germany 
Total volume of master mix for 1 sample: 29µl. 
 
cDNA synthesis master mix (1 reaction): 
5x reaction buffer 4µl                      Bioline, Luckenwalde, Germany 
dNTPs (10mM) 1µl                       Bioline, Luckenwalde, Germany 
HPLC- H2O 2.75µl                          AppliChem, GmbH, Germany 
BioScript reverse transcriptase (200U/µl) 0.25µl        Bioline, Luckenwalde, 
Germany 
Total volume of master mix for 1 sample: 8µl. 
 
 
2.6 Primers 
All primer sequences were created using the online software at 
http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi developed by 
the Whitehead Institute for Biomedical Research (Rozen and Skaletsky, 2000) 
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(Table. 1). Primer oligo-nucleotides were purchased from Operon (Köln, 
Germany). 
 
 
2.7 Consumables 
Polypropylene round-bottom tube                   FALCON®, NJ, USA 
6-well flat bottom culture plate       Greiner-bio-one GmbH, Frickenhausen, 
Germany 
75cm2 Carrel flask                                    TPP®, Switzerland 
1.5ml Eppendorf centrifuge tube            Eppendorf, Hamburg, Germany 
15ml conical tube         Greiner-bio-one GmbH, Frickenhausen, Germany 
50ml conical tube         Greiner-bio-one GmbH, Frickenhausen, Germany 
Cuvette                                                 Bio-Rad, USA 
10µl white tips                                          Roth, Germany 
200µl yellow tips                                        Roth, Germany 
1000µl blue tips                                        Roth, Germany 
2ml single-use syringe                 B/BRAUN Melsungen AG, Germany 
5ml single-use syringe                 B/BRAUN Melsungen AG, Germany 
10ml single-use syringe                B/BRAUN Melsungen AG, Germany 
PCR tubes               Greiner-bio-one GmbH, Frickenhausen, Germany 
 
 
2.8 Apparatus 
20℃ Refrigerator                                   BOSCH, Germany 
80℃ Refrigerator                                   BOSCH, Germany 
37℃ CO2 Incubator                                 Heraeus, Germany 
Water bath                                            Lauda, Germany 
Centrifuge                                          Heraeus, Germany 
Laminar flow cabinet                                 Heraeus, Germany 
Shaking incubator                                   Heraeus, Germany 
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PTC-200 Peltier thermal cycler       Biozym, Hessisch Oldendorf, Germany 
UV spectrophotometry                    Eppendorf, Hamburg, Germany 
DPU 414 THERMAL PRINTER               Seiko Instruments Inc, Japan 
ABI PRISM 310 Genetic Analyzer  Applied Biosystems, Darmstadt,Germany 
Fluorescence phase contrast microscope                 Zeiss, Germany 
Heating block                                          VWR, Germany 
LTF Bio ID software                          LTF, Wasserburg, Germany 
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3.                  Methods 
 
3.1 Culturing clonal cell lines 
The E. coli were inoculated onto freshly prepared Luria-Bertani (LB) ampicillin 
medium plate by using a sterile loop. The plates were incubated into a 
humidified atmosphere for 15-20 hours at 37℃. 
 
A single E. coli colony was isolated from the plate using autoclaved tip to 5ml 
polypropylene round-bottom tube, which contained 1.5ml LB medium and 
1.5µl ampicillin. E. coli colony was incubated at 37℃ with constant shaking 
(200-250 rpm) overnight. 
 
 
3.2 Purification and sequencing of plasmid DNA 
Plasmid DNA was purified by NucleoSpin® Plasmid Mini Kit according to the 
manufacturers protocol. With the NucleoSpin plasmid method, the pelleted 
bacteria were resuspended (buffer A1) and plasmid DNA was liberated from 
the E. coli host cells by SDS/alkaline lysis (buffer A2). The resulting lysate 
was neutralized and appropriate conditions for binding of plasmid DNA to the 
silica membrane of the NucleoSpin Plasmid QuickPure column by buffer A3 
were created. SDS precipitated and cell debris was then pelleted by a 
centrifugation step, the supernatant was loaded onto the column. 
Contaminations like salts, metabolites, nucleases and soluble 
macromolecular cellular components were removed by only a single washing 
step with buffer AQ. Pure plasmid DNA was finally eluted under low ionic 
strength conditions with slightly alkaline buffer AE (5mM Tris-Cl, pH 8.5). 
 
To determine the nucleotide order in the plasmid, the sequence was analyzed 
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using the Big Dye Terminator v1.1 Cycle Sequencing Kit and the ABI PRISM 
310 Genetic Analyzer according to the manufacturers instructions. This 
method labeled the terminators instead of labeling the primer in the method of 
Sanger dideoxy chain termination. The major advantage of this approach is 
that the complete sequencing set can be performed in a single reaction, rather 
than four different reactions needed in the labeled-primer approach. The dye 
terminator method was accomplished by labeling each of the 
dideoxynucleotide chain-terminators with a separate fluorescent dye, which 
fluoresced at a different wavelength and was therefore easier to perform 
compared to the Sangers method. 
 
3.2.1 Mini-purification of plasmid DNA 
 
3.2.1.1 Cultivate and harvest bacterial cells 
Using 1.5ml of a saturated E. coli LB culture, cells were pelleted in a standard 
benchtop microcentrifuge for 30s at 11000x g. The supernatant was discarded 
carefully. As much of the supernatant as possible should be removed. 
 
3.2.1.2 Cell lysis 
250µl buffer A1 was added. The cell pellet was resuspended by vigorous 
vortexing. No cell clumps should remain in the suspension before the addition 
of buffer A2. 
 
250µl buffer A2 was added. Mix the pellet gently by inverting the tube 6-8 
times. Do not vortex. The pellet was incubated at room temperature for a 
maximum of 5min. Do not vortex because chromosomal DNA might be 
released by mechanical shearing. 
 
300µl buffer A3 was added. Mix gently by inverting the tube 6-8 times. Do not 
vortex. 
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3.2.1.3 Clarification of lysate 
The lysate was centrifuged for 5min at 11000x g at room temperature. 
 
3.2.1.4 Bind DNA 
NucleoSpin Plasmid QuickPure column was placed in a 2ml collecting tube 
and the supernatant was loaded from the last step onto the column. The 
supernatant was centrifuged for 1min at 11000x g. The flow-through was 
discarded. 
 
3.2.1.5 Wash silica membrane 
NucleoSpin Plasmid QuickPure column was placed back into the 2ml 
collecting tube and 450µl buffer AQ was added. The column was centrifuged 
for 3min at 11000x g. The flow-through was discarded. 
 
3.2.1.6 Dry silica membrane 
The drying of the NucleoSpin Plasmid QuickPure column was performed by 
the 3min centrifugation in the last step. 
 
3.2.1.7 Elute and detect highly pure DNA 
The column was place in a 1.5ml Eppendorf tube and 50µl buffer AE was 
added. The column was incubated 1min at room temperature and was 
centrifuged for 1min at 11000x g.  
 
Plasmid yield was detected by using 4µl aliquotes plus 46µl HPLC-H2O by UV 
spectrophotometry with an A260/280 ratio approaching 2.0 that indicates the 
purity of the plasmid. 
 
3.2.2 Sequencing PCR 
DNA sequencing reaction was run by using a PTC-200 Peltier thermal cycler 
in a total volume of 20µl including 4µl Big Dye Terminator v1.1 Ready 
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Reaction Mix; 2µl Big Dye Sequencing v1.1 buffer; 1µl primer LKO.1 
(5-GACTATCATATGCTTACCGT-3) (5pmol/µl); 150-300ng DNA; HPLC- H2O, 
which plus the volume of DNA equals to 13µl. The sequencing reaction steps 
were as follows: 4min at 94℃, 24 cycles of 94℃ for 30s, 50℃ for 1min and 
60℃ for 1min, with a final 72℃ step for 5min. 
 
3.2.3 Clean-up of sequencing-PCR products 
Clean-up of sequencing reaction products was performed by using the 
NucleoSEQ Kit. (1) Dried gel resin in NucleoSEQ column was spin down 30s 
at 3500rpm; (2)600µl HPLC- H2O was added and vortexed to hydrate the gel 
matrix. Air bubbles was removed by vortexing or tapping the column; (3) gel 
matrix was incubated at 4℃ or room temperature at least 30min; (4) the 
settled gel matrix was resuspended by inverting of vortexing the spin column 
several times. Air bubbles should not be visible; (6) the column was cut 
closure at the bottom and spun 2min at 3500rpm, collection vial was 
discarded; (7) column was place onto an Eppendorf tube; (8)20µl Seq-PCR 
products were carefully loaded drop-wise onto the center of the gel resin,; (9) 
the sample was eluted by centrifuging the column for 5min at 3500rpm, the 
column was discarded, sample was dried or used directly. 
 
3.2.4 Ethanol precipitation 
Ethanol precipitation steps of the sequencing reaction products were as 
follows: (1) 3µl 3M Na-Acetate and 80µl 100％ ethanol was added, vortexed 
briefly and incubated 15min at room temperature; (2) the products were spun 
20min at 13000rpm, supernatant was discarded and then 250µl 70％ ethanol 
was added and vortexed briefly; (3) the products were spun 10min at 
13000rpm, supernatant was spun as above and the DNA pellet was dried for 
at least 10min; (4) 15µl TSR was added to the dried pellet; (5) the DNA was 
denatured in PTC-200 Peltier thermal cycler at 94℃ for 4min and then the 
products was placed on ice for 3min and was spun about 10s at 6000rpm. 
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3.2.5 Sequencing samples in sequencer 
The samples were placed in the ABI PRISM 310 Genetic Analyzer and the 
analysis of the sequencing reaction was performed according to the 
manufacturer. 
 
3.2.6 Clarify the target gene 
The sequences were checked at: www.sigma-aldrich.com/missionsearch 
using RefSeq accession numbers to identify the correct sequence of the 
insert of every shRNA clone. 
 
3.2.7 Midi-purification of plasmid DNA 
Validated plasmid DNA was purified by HiSpeed Plasmid Midi and Maxi Kit 
according to the manufacturers instructions for further transfection. The Midi 
plasmid purification protocols were based on a modified alkaline lysis 
procedure, followed by binding of plasmid DNA to Anion-Exchange Resin 
under appropriate low-salt and pH conditions. RNA, proteins, dyes, and 
low-molecular-weight impurities were removed by a medium-salt wash. 
Plasmid DNA was eluted in a high salt buffer and then concentrated and 
desalted by isopropanol precipitation.  
 
3.2.7.1 Cultivate and harvest bacterial cells 
A single colony was picked from a freshly streaked selective LB plate and 
used to inoculate a starter culture of 2-5 ml LB medium containing the 
selective antibiotic (ampicillin). The culture was incubated for approx. 8 h at 
37°C with vigorous shaking (300 rpm). Then the starter culture was diluted 
1/500 to 1/1000 into 50 ml selective LB medium and grown at 37°C for 12-16h 
with vigorous shaking (300 rpm). The culture should reach a cell density of 
approximately 3-4 x 109 cells per milliliter, which typically corresponds to a 
pellet wet weight of approximately 3g/liter. The bacterial cells were harvested 
by centrifugation at 6000 x g for 15 min at 4°C. All traces of supernatant were 
removed by inverting the open centrifuge tube until all medium has been 
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drained.  
 
3.2.7.2 Cell lysis 
The bacterial pellet was resuspended in 6ml buffer P1, to which RNase A was 
added. For efficient lysis to occur it was important to use a vessel that was 
large enough to allow complete mixing of the lysis buffers. The bacteria 
should be resuspended completely by vortexing or pipetting up and down until 
no cell clumps remain. 6 ml or Buffer P2 was added, mixed thoroughly by 
vigorously inverting the sealed tube 4-6 times and incubated at room 
temperature for 5 min. The mixture should not be vortexed, as this would 
result in shearing of genomic DNA. The lysate should appear viscous. The 
lysis reaction should not proceed for more than 5 min.  
 
During the incubation the QIAfilter Cartridge was prepared: The cap was 
screwed onto the outlet nozzle of the QIAfilter Midi Cartridge. The QIAfilter 
Cartridge was placed into a convenient tube. 
 
3.2.7.3 Clarification of lysate 
6 ml or chilled Buffer P3 was added to the lysate, mixed immediately and 
thoroughly by vigorously inverting the tube 4-6 times. The lysate should not be 
incubated on ice. 
 
After addition of Buffer P3, a fluffy white precipitate containing genomic DNA, 
proteins, cell debris, and KDS became visible. The buffers must be mixed 
completely. If the mixture appeared still viscous and brownish, more mixing 
was required to completely neutralize the solution. It was important to transfer 
the lysate into the QIAfilter Cartridge immediately in order to prevent later 
disruption of the precipitate layer. The lysate was incubated at room 
temperature for 10 min. This 10 min incubation at room temperature was 
essential for optimal performance of the QIAfilter Cartridge. Do not agitate the 
QIAfilter Cartridge during this time. A precipitate containing proteins, genomic 
DNA, and detergent would float and form a layer on top of the solution. This 
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ensured convenient filtration without clogging.  
 
A HiSpeed Midi or Tip was equilibrated by applying 4 ml Buffer QBT and the 
column was allowed to empty by gravity flow. Flow of buffer will begin 
automatically by reduction in surface tension due to the presence of detergent 
in the equilibration buffer. The HiSpeed Tip was allowed to drain completely.  
 
The cap was removed from the QIAfilter outlet nozzle. The plunger was gently 
inserted into the QIAfilter Midi Cartridge and the cell lysate was filtered into 
the previously equilibrated HiSpeed Tip until all of the lysate has passed 
through the QIAfilter Cartridge, but did not apply extreme force. Approximately 
15 ml of the lysate was generally recovered after filtration. 
 
3.2.7.4 Bind and wash DNA 
The cleared lysate was allowed to enter the resin by gravity flow. The 
HiSpeed Midi Tip was washed with 20 ml or Buffer QC. Buffer QC was 
allowed to move through the HiSpeed Tip by gravity flow. 
 
3.2.7.5 Elute and precipitate DNA 
The DNA was eluted by 5 ml or Buffer QF. The eluate was collected in a 15ml 
conical tube. The DNA was precipitated by adding 3.5 ml room temperature 
isopropanol to the eluted DNA and was mixed and incubated at room 
temperature for 5 min. All solutions should be at room temperature in order to 
minimize salt precipitation. During the incubation the plunger was removed 
from a 20 ml syringe and the QIAprecipitator Midi Module was attached onto 
the outlet nozzle. The QIAprecipitator was placed over a waste bottle, the 
eluate/isopropanol mixture was transfered into the 20 ml syringe, and the 
plunger was inserted. The eluate/isopropanol mixture was filtered through the 
QIAprecipitator using constant pressure. The QIAprecipitator was removed 
from the 20 ml and the plunger was pulled out. The QIAprecipitator was 
reattached and 2 ml 70% ethanol was added to the syringe. The DNA was 
washed by inserting the plunger and pressing the ethanol through the 
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QIAprecipitator using constant pressure. Then the QIAprecipitator was 
removed from the 20 ml syringe and the plunger was pulled out. The 
QIAprecipitator was attached to the 20 ml syringe again, the plunger was 
inserted, and the membrane was dried by pressing air through the 
QIAprecipitator quickly and forcefully. Repeat this step. 
 
The outlet nozzle of the QIAprecipitator was dried with absorbent paper to 
prevent ethanol carryover. The plunger was removed from a new 5 ml syringe 
and the QIAprecipitator was attached onto the outlet nozzle. The outlet of the 
QIAprecipitator was held over a 1.5 ml collection tube. 1 ml of Buffer TE was 
added to the 5 ml syringe. The plunger was inserted and the DNA was eluted 
into the collection tube using constant pressure.  
 
Plasmid yield was detected by using 4µl probes plus 46µl HPLC-H2O by UV 
spectrophotometry with A260/280 ratio, indicating the purity of plasmid. 
 
 
3.3 Culture 293FT cells 
 
3.3.1 Thawing and culture cells 
293FT cells were stored in liquid nitrogen and were thawed quickly in a 37℃ 
water bath. Just before the cells were completely thawed, the outside of the 
vial was decontaminated with 70% ethanol. Subsequently, the cells were 
transfered to a sterile 15ml tube containing PBS. The cells were briefly 
centrifuged at 150-200x g and resuspended in 2ml complete medium without 
antibiotic. Then cells were transferred to T-75cm2 flask containing 10ml 
prewarmed, complete medium. The cells were incubated overnight at 37℃ 
for allowing the cells to attach to the bottom of the flask. The next day, the 
medium was aspirated off and was replaced with fresh, complete medium, 
which was replaced every 2-3 days. Since L-glutamine slowly decays over 
time, the complete medium needs to be supplemented with 2mM L-glutamine. 
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This ensured that the concentration of L-glutamine in complete medium will 
not get too low over time due to its slow degradation. 
 
3.3.2 Subculturing cells 
At about 80-90％ confluence, cell density should be above 5 x 105, cells were 
subcultured after exposure to trypsin/EDTA. Viability and cell density was 
determined by trypan blue stain (0.4%). 
 
3.3.2.1 Determining viability and cell density 
The surface of hemocytometer chamber and cover lip were cleaned with 70% 
ethanol carefully. The coverlip was breathed to humidify and was placed on 
the chamber plate, so called Newton rings should become visible and cover 
lip needs to fit well. 50µl cells was incubated in the 50µl 0.4% trypan blue 
solution (final concentration: 0.2%) for 1-2minutes. 10µl of this suspension 
was pipetted to the chamber and the chamber was placed under the phase 
contrast microscope, 10x objective focus was used. Living cells were counted 
in 4 large squares and the viability was calculated: Cells/ml = (sum of living 
cells/ numbers of large squares) x 104x 2. Cells viability should be at least 
95% for healthy log-phase cultures. 
 
3.3.2.2 Subculturing cells 
All medium was removed from the flask and the cells were washed once with 
10ml PBS to remove excess medium and serum. 2ml of trypsin/EDTA solution 
was added to the monolayer and incubated 1-5min at room temperature until 
cells detach. The cells were checked under a microscope and it was 
confirmed that most of cells have detached. Viable and total cells were 
determined and cells were seeded at the density 2-5x 104 /cm2. 
 
 
3.4 RNAi transfection by Lipofectamine 2000 
Before transfection, the subcultured cells should be at passage 10 or lower. 
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Complexes were preparered using a DNA (µg) to Lipofectamine 2000 (µl) 
ratio of 1:2 to 1:3 for cell lines.  
 
One day before transfection, 0.5-2x 105 cells in 2ml of growth medium without 
antibiotics were plated per 6-well plate so that cells will be 90-95% confluent 
at the time of transfection. For each transfection sample, complexes were 
prepared as follows: Dilute 4µg DNA in 250µl DMEM (high glucose) without 
serum. Mix gently. Mix Lipofectamine 2000 gently before use, then dilute it 
10µl in 250µl DMEM (high glucose). Incubate for 5 minutes at room 
temperature. After the 5 minute incubation, combine the diluted DNA with 
diluted Lipofectamine 2000 (total volume = 500µl). Mix gently and incubate 
for 20 minutes at room temperature (solution may appear cloudy). Add the 
500µl of complexes to each well containing cells and medium. Mix gently by 
rocking the plate back and forth. Incubate cells at 37°C in a CO2 incubator for 
18-48 hours prior to testing for transgene expression.  
 
The TurboGFP Control Vector was used as a positive transfection control and 
untreated cells, that provided a reference point for comparing all other 
samples, were employed as negative control. 
 
 
3.5 Total RNA isolation and reverse 
transcriptase polymerase chain reaction 
(RT-PCR) 
 
3.5.1 Total RNA isolation 
Total cellular RNA was isolated from cells that underwent transfection and 
controls, which were obtained from confluent untransfected cells, at the time 
of 2, 4, 6 days after transfection respectively, by using the NucleoSpin® RNA 
Ⅱ Mini Kit.  
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One of the most important aspects in the isolation of RNA is to prevent the 
degradation of RNA during the isolation procedure. With the NucleoSpin RNA 
methods, cells are lysed by incubation in a solution containing large amounts 
of chaotropic ions. This lysis buffer immediately inactivated RNases  which 
are present in virtually all biological materials  and created appropriate 
binding conditions which favored the adsorption of RNA to the silica 
membrane. Contaminating DNA, which was also bound to the silica 
membrane, was removed by an rDNase solution which was directly applied 
onto the silica membrane during the preparation. Simple washing steps with 
two different buffers removed salts, metabolites and macromolecular cellular 
components. Pure RNA was finally eluted under low ionic strength conditions 
with RNase-free water. The purity of RNA was analyzed by using 2µl probes 
plus 48µl HPLC-H2O by UV spectrophotometry. 
 
350µl buffer RA1 and 3.5µl β-mercaptoethanol were added to the cell pellet or 
to ground tissue and vortexed vigorously. Viscosity and the lysate were 
removed and cleared by filtration through NucleoSpin Filter units: 
NucleoSpin® Filter units (violet ring) were placed in a collecting tube, the 
mixture and centrifuge were applied for 1 min at 11,000 x g. In case of visible 
pellet formation (depending on sample amount and nature) the supernatant 
was transferred without any formed pellet to a new 1.5 ml centrifuge tube. The 
Filter unit was discarded and 350µl ethanol (70%) was added to the 
homogenized lysate and mixed by pipetting up and down (5 times). For each 
preparation, one NucleoSpin RNA II column (light blue ring) was placed in a 2 
ml centrifuge tube. Lysate was pipetted up and down 2-3 times and the lysate 
was loaded to the column and centrifuged for 30 s at 11,000x g. The column 
then was placed in a new collecting tube. 350µl MDB (Membrane Desalting 
Buffer) was added and centrifuged at 11,000 x g for 1 min to dry the 
membrane. 95µl DNase reaction mixture was applied directly onto the center 
of the silica membrane of the column and incubated at room temperature for 
15 min. 200µl buffer RA2 was added to the NucleoSpin RNA II column and 
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centrifuged for 30 s at 11,000x g. The column was then placed into a new 
collecting tube. 600µl buffer RA3 was added to the column centrifuged for 30s 
at 11,000 x g. Flowthrough was discarded and the column was placed back 
into the collecting tube. 250 µl buffer RA3 was added to the column and 
centrifuged for 2 min at 11,000 x g to dry the membrane completely. The 
column was then placed into a nucleasefree 1.5 ml microcentrifuge tube. The 
RNA was eluted in 60µl RNase-free H2O and centrifuged at 11,000 x g for 1 
min. 
 
3.5.2 cDNA synthesis 
cDNA was synthesized from identical amounts of 1µg total RNA using 
BioScript reverse transcriptase and random hexamers according to the 
manufacturer's instructions. 
 
Appropriate volume of HPLC- H2O was pipetted into autoclaved 1.5ml 
Eppendorf tubes. RNA-suspension was added, RNA plus water should be 
exactly 11µl. 1µl (1µg/µl) random hexamers were added per reaction. The 
tubes should be placed into a heating block at 70℃ for 5min then on ice for 
5min, spun briefly. For 1 sample, 4µl 5x reaction buffer, 1µl 10mM dNTPs, 
2.75µl HPLC- H2O, 0.25µl 200U/µl BioScript reverse transcriptase were 
added respectively. Samples were placed at room temperature for 10min then 
in a heating block at 42℃ for 60min then place at 70℃ for 10min and 
centrifuged briefly and 30µl HPLC- H2O was added. 
 
3.5.3 PCR 
PCR reactions were run in a volume of 30µl containing 1µl cDNA for the 
house keeping gene eukaryotic translation elongation factor 1 alpha (EF 1ɑ) 
applying 35-45 amplification cycles (Schütze et al., 2005b). For each sample, 
the PCR reaction master mix consisted of 0.5 units BIOTAQ DNA polymerase, 
1mM NH4 reaction buffer with 1.7mM MgCl2, 0.3mM dNTPs, 5pmol forward 
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and 5pmol reverse primer plus 1µl cDNA. PCR reaction steps were as follows: 
3min at 94℃, 35-45cycles of 94℃ for 30s, 48-60℃ for 1min and 72℃ for 1min, 
with a final 72℃ step for 5min. 
 
 
3.6 Gel electrophoresis and densitometry 
3.6.1 Gel electrophoresis 
The appropriate percent content of agarose in the gel depends on the size of 
the PCR-products that were to be separated in gel electrophoresis. 
 
Appropriate amount of agarose was weighted in Erlenmeyer flask and 100ml 
or 50ml of 0.5% TBE-buffer was added. Agarose was then heated in a 
microwave oven until the agarose was completely dissolved. 5µl 
ethidiumbromide per 100ml was added to gel solution. The gel was poured 
and a comb was inserted. After 30min, when the gel hardened it was placed 
into an electrophoresis chamber and the comb was removed. 
 
Then 1.5µl of 10% DNA-loading-dye and 10µl PCR-products were placed into 
an eppendorf tube. 10µl of sample was pipetted into each slot of the gel and 
5µl DNA-ladder was added into one of the slot. Gel running conditions: 145V 
for about 45min. 
 
PCR-bands were monitored and semiquantitatively analyzed using the LTF 
BioCaptMW software (LTF, Wasserburg, Germany). 
 
3.6.2 Densitometry 
Densitometry is the quantitative measurement of optical density in 
light-sensitive materials, such as photographic film, due to exposure to light. 
Optical density is a result of the darkness of a developed picture and can be 
expressed absolutely as the number of dark spots (i.e., silver nitrate grains in 
developed films) in a given area. 
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PCR product intensities densitometry was performed using an LTF 
densitometer and the bioprofile software (LTF, Wasserburg, Germany) 
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4.                  Results 
 
4.1 Strategy of work 
The goal of the project was to establish knock down of mRNA in human 
mesenchymal stem cells. Since these cells are difficult to transfect, a viral 
approach is needed to achieve sufficient expression of e. g. shRNA in a high 
percentage of cells to allow for an efficient silencing of corresponding mRNAs. 
For this purpose for every gene product of interest, a number of shRNA 
clones have to be tested to detect an individual shRNA with sufficient efficacy. 
 
Lentiviral systems for shRNA approaches have recently become available. 
The principal advantage of the lentiviral system is that it allows gene silencing 
in nondividing cells and therefore expands the usefulness of the RNAi-based 
gene silencing system. Lentivirus-delivered shRNAs are capable of specific, 
highly stable and functional silencing of gene expression in a variety of cell 
types. 
 
The MISSION-consortium (in association with Sigma Inc.) was established 
with the goal to silence every human and mouse mRNA by a lentiviral shRNA 
strategy and to provide the individual clones to the academic community at a 
reduced rate. It was claimed that MISSION shRNAs are expressed within 
the cell from a plasmid and serve as potent gene silencing agents that allow 
for long-term gene knockdown. The plasmids expressing the shRNAs can be 
used either directly for transfection to achieve transient gene knock-down or 
as lentiviral particles after transfection of 293 cells along with packaging and 
envelope plasmids for long-term experiments by integration into the host 
genome. Features of the MISSION shRNA-clones are: (1) easy - avoid 
handling of RNAs and Dicer treatment; (2) comprehensive, average of 3-5 
shRNA constructs per target gene; (3) economical, vector-based system 
provides a renewable resource compared to siRNA; (4) flexible, transient or 
 
4. Results                                                              
 
 
52
stable silencing (puromycin selection) for long term expression or phenotypic 
studies; (5) solutions, lentiviral system for transduction of difficult cell lines 
(non-dividing cells and primary cells); (6) quality, all clones are sequence 
verified; (7) controls provides in parallel (GFP, scrambled shRNA etc). 
 
Since the viral transfection of MSCs is a time consuming process that involves 
transfection of 293 FT cells plus transduction of target cells, for this thesis the 
following approach was chosen: genes of interest were checked for 
expression in 293FT cells by RT-PCR. These gene products can be silenced 
in 293FT cells simply by transfection of shRNA clones and efficacy was 
subsequently tested by RT-PCR. Beyond this thesis then the project can 
proceed with effective clones to transduce primary MSCs with individual 
shRNA clones identified as effective silencing tool in this thesis. 
 
 
4.2 Selection of gene products to be targeted 
by shRNA  
Bioinformatic analysis of microarray experiments, that compared 
transdifferentiated human mesenchymal stem cells with normally 
differentiated human mesenchymal stem cells exhibited large numbers of 
reproducibly regulated genes for both, adipogenic and osteogenic 
transdifferentiation. Subsequent bioinformatical tools were used to allow for a 
ranking of regulated genes according to reproducibility of regulation, extend of 
regulation. The top 40 gene products of this ranking represent the top 
potential key factors associated with transdifferentiation of adipocytes and 
osteoblasts, respectively. 
 
From the homepage of the MISSION at the time of beginning of the project we 
selected 8 genes to be targeted by shRNA clones (Table 1). This selection 
was from the previously mentioned ranking list and according to data 
available in the literature as well as the availability of shRNA clones from the 
 
4. Results                                                              
 
 
53
MISSION project. These genes can all be expressed in 293T cells according 
to the literature in the homepage of the MISSION. Each gene is represented 
by a target set that consists of an average of 4-5 individual constructs or 
clones targeting different regions of the gene sequence. 
 
4.3 Preparation of shRNA clones and 
sequencing  
Totally, eight shRNA clone sets that consisted of 4-5 individual clones with 
different shRNA constructs, were isolated from glycerol stocks and sequenced. 
From altogether 39 clone constructs received, 26 plasmids with clones hairpin 
constructs were gained (Fig.3; Table 2). Apart from one clone set, the 
remaining 7 clone sets are represented by at least 2 distinct shRNA clones, 
respectively. 
 
After checking the sequences, we knew that these 26 constructs hairpin 
sequences were targeted to 8 different mRNAs respectively, (coding for 7 
known proteins and 1 hypothetical protein). Most regions that the shRNA 
targeted were in the CDS, except 4 hairpin sequences that targeted in the 
3-UTR. 
 
 
Fig 3. Example of one of sequences of the shRNA. The vector map of this shRNA is 
CCGGGCTATCTTACAGACGCATGAACTCGAGTTCATGCGTCTGTAAGATAGCTTTTTG. In 
the map, sense stem sequence is GCTATCTTACAGACGCATGAA and aniti-sense stem 
sequence is TTCATGCGTCTGTAAGATAGC. The loop sequence is CTCGAG. 
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4.4 RT-PCR of genes of interest in 293FT cells 
In order to know whether these genes of interest are expressed in 293FT cells, 
and therefore could be targeted by shRNA transfections, we used RNA 
isolated from 293FT cells and primers showed in table 1 to perform RT-PCR. 
It was confirmed that all these genes of interest were expressed in 293FT 
cells. 
 
Fig 4. Examples of some genes of interest were expressed in 293FT cells. From left to right, 
the bands represent SERPINE1, SNF1LK2, PDE4b, DDIT4, BIRC3, PLCB4, ID4, EPHA2, 
DDAH1, RGS4, COFEB. 
 
 
4.5 RNAi transfection by Lipofactamine 2000 
Before transfection, the 293FT cells should reach 90-95% confluence. 
Otherwise, the cells would die because Lipofectamine is toxic. We found that 
the cells grew slowly when adding the Lipofactamine 2000 in transfections. 
 
Using a plasmid encoding the green fluorescent protein the transfection 
efficacy was controlled over time to establish the appropriate transfection 
conditions according to length of treatment and concentration of lipofectamine 
and plasmid DNA for the 293 cells. 
 
From several experiments the following conditions were established to 
achieve optimal transfection efficacy as is presented in fig. 4. 4µg DNA and 
10µl Lipofectamine 2000 were diluted in 250µl DMEM (high glucose) 
without serum, respectively. After the 5 minute incubation, combine the 
diluted DNA with diluted Lipofectamine 2000 (total volume = 500µl). Mix 
gently and incubate for 20 minutes at room temperature. 500µl of complexes 
were added to each sample. Cells were incubated at 37°C in a CO2 incubator 
for 18-48 hours prior to testing for transgene expression. After 1 day of 
transfection, there was a little cells turning green in the positive control well 
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where there was Turbo-GFP vector. While after 2 days of transfection, the 
cells turn green sharply (Fig. 5).  
A 
   
 
B 
   
 
C 
   
 
Fig.4. Phase-contrast images of Turbo-GFP visualized by white light and by fluorescent light 
after transfection. (A), (B) and (C) indicate images 2, 4, 6 days after transfection respectively. 
 
 
4.6 RT-PCR after transfection 
From the 26 constructs sequences, we found that there was one construct 
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hairpin sequence (TRCN0000007013) targeted in the coding sequence of the 
gene PLCB4 that can knock down the targeted gene (Fig.6). Our experiment 
showed that optimal knockdown at the mRNA level was usually reached at 
48-96 hours after transfection. This correlates with results reported by 
Krueger, et al (2007) (Fig 7). 
 
                          
 
 
 
 
 
Fig. 6. A: transfection of three different hairpin sequence targeted in gene PLCB4. B: EF-1α 
as the house keeping gene and control. RNA samples were isolated at the indicated days of 
transfection. RT-PCR was run at the annealing temperature of 48℃, 45cycles and 3µl cDNA 
for PLCB4 as well as an annealing temperature of 54℃, 35cycles and 1µl cDNA for EF-1α 
which reported the quality of the cDNA and served as a house keeping gene. 
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Fig 7. Densitometry analysis of these three clones. Data showed that optimal knockdown at 
the mRNA level was usually reached at 48-96 hours after transfection in clone 7009.
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5.               Discussion 
The goal of this project is to establish knock down of mRNAs in human 
mesenchymal stem cells. Genes to be targeted stem from a project that 
identified candidate genes for controlling transdifferentiation events in 
adipogenic and osteogenic transdifferentiation processes. Using a list of the 
top 40 ranked gene products 8 gene targets were selected for gene silencing. 
Since the viral transfection of MSCs is a time consuming process, genes of 
interest were checked for expression in 293FT cells by RT-PCR. These gene 
products can be silenced in 293FT cells simply by transfection of shRNA 
clones. The efficacy of this approach was tested by RT-PCR. 
 
 
5.1 Turbo-GFP is a useful tool for in vivo imaging 
 
5.1.1 Characteristics of GFPs 
Four decades ago, GFP was discovered in the Pacific Northwest jellyfish 
Aequorea victoria (Johnson et al, 1962) where it acts as a secondary emitter 
in a bioluminescent system based on the Ca2+-dependent photoprotein 
aequorin. But it was not until 1994, that this protein attracted attention after 
cloning and successful heterologous expression of the gfp gene (GenBank 
accession no. U17997) (Chalfie et al, 1994). GFP and its mutants soon 
became popular tools for cell and molecular biology and, during the past few 
years, the great spectral and phylogenetic diversity of GFP-like proteins has 
been characterized in marine organisms; furthermore, several useful mutant 
variants of GFPs have been generated. Together with engineered mutant 
variants, FPs are a family of homologous 25-30 kDa polypeptides and now 
available for the entire visible spectrum: from 450 to 650 nm. A novel 
green-FP, the-non-aggregating mutant of fast maturating Copepoda GFP  
named TurboGFP and the monomeric mutant mAG1 (Azami Green) 
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(Karasawa et al, 2003) of Galaxeidae coral GFP have also been produced 
recently. 
 
5.1.2 Applications of GFPs 
FPs are widely used as noninvasive probes to study different biological 
models from individual cells to whole organisms. The use of FPs enables the 
tracking of every step of the protein of interest: expression, localization, 
movement, interaction and activity in the cell, tissue or organism. The main 
applications of FPs are: visualization of target-gene promoter up- and 
down-regulation, protein labeling, detection of proteinprotein interactions, 
tracking protein movement and monitoring cellular parameters using 
FP-based fluorescent sensors. 
 
5.1.2.1 Monitoring of gene expression 
The gene encoding a FP is cloned under the control of the target promoter, 
whereby activity of the promoter can be monitored by the magnitude of the 
fluorescent signal. Although this approach has a reduced sensitivity 
compared with enzyme-based assays, it has certain advantages and a much 
wider range of applications when using specially designed FP variants. The 
oligomeric state of an FP is important when applied to protein labeling but it 
does not have a negative effect on monitoring of promoter activity. Therefore, 
many new FPs are suitable for these applications, making it possible to detect 
the activity of several different promoters with up to 4-5 distinct fluorescent 
colors, simultaneously. 
 
Moreover, FPs allow time-scale monitoring of promoter activity. The first 
approach is to use destabilized FPs (Li et al, 1998) to obtain a fluorescent 
signal only during the period of promoter activity. Here, fast-maturating FPs 
are desirable to provide a minimal delay between the promoter activation and 
fluorescent signal appearance. The second approach is to use the so-called 
Timer FP, which is capable of a gradual change in fluorescence color over 
time: from blue to green, and then to red (Terskikh et al, 2000); therefore 
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Timer provides retrospective information about the length of time the promoter 
is active. 
 
Recently, a novel technique to detect promoter activity has been developed 
using a so-called split FP. This is a FP expressed as two separate parts but 
capable of reconstituting to the whole functional protein when cloned fewer 
than two promoters of interest; the fluorescent signal occurs only when both 
promoters are active. Moreover, by combining separate parts, each carrying 
point mutations responsible for spectral shifts, one can obtain information 
about the combinations of promoters of interest active in a system (Zhang et 
al, 2004). 
 
5.1.2.2 Protein labeling 
The most widely used FP application is probably protein tagging, achieved by 
cloning a FP in frame with the target protein at either its N- or C-terminus. 
Numerous experiments with GFP mutants have demonstrated that most 
fusion proteins created this way are fully functional; however, in each 
particular case, the researcher must determine whether the function of the 
FP-tagged protein remains natural. An oligomeric state becomes crucial when 
fusing GFP-like proteins to a protein of interest and, in most cases, attempts 
to use tetrameric FPs to label cellular proteins result in aggregation of the 
chimera and disturbance to the target protein function and localization. 
Although several other solutions have been proposed to avoid this 
complication, the answer lies in developing monomeric FPs with the desired 
spectral characteristics (Ando et al, 2004). 
 
5.1.2.3 Protein mobility 
Over the past few years, considerable progress has been made in developing 
the so-called photoactivatable FPs. These proteins are capable of a 
many-fold increase in fluorescence intensity at certain excitation/emission 
wavelengths, in response to irradiation with specific light. This property can be 
used to switch-on a fluorescent signal, using a beam of focused light, and 
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then track the movement of labeled cells, organelles or individual proteins. 
Until recently, photobleaching techniques, such as fluorescence recovery 
after photobleaching (FRAP), fluorescence loss in photobleaching (FLIP), 
flurescence correlation spectroscopy (FCS) and fluorescence resonance 
energy transfer (FRET) were the major tools to study protein mobility (Schmid 
and Neumeier, 2005). Photoactivatable FPs provide a more precise, direct 
and less damaging way to study movement of proteins. 
 
In our research, the Turbo-GFP, an improved variant of the green fluorescent 
protein copGFP cloned from the copepoda Pontellina plumata, control vector 
is an 8347 base pair lentiviral plasmid vector that contains a gene encoding 
Turbo-GFP, under the control of the CMV promoter. It is useful as a positive 
transfection control in experiments using the shRNA clones. 
 
 
5.2 PLC-β4 is a multifunction protein 
Phospholipase C (PLC) constitutes a large family of mammalian hydrolytic 
phosphodiesterase enzymes that participate in phosphatidylinositol (PIP2) 
metabolism and lipid signaling pathways in a calcium dependent manner. 
Currently, the superfamily consists of six sub-families comprising a total of 13 
separate isoforms that differ in their mode of activation, catalytic regulation, 
cellular localization, membrane binding avidity, and tissue distribution. All are 
capable of catalyzing the hydrolysis of PIP2 into two important second 
messenger molecules, which go on to alter cell responses such as 
proliferation, differentiation, apoptosis, cytoskeleton remodeling, vesicular 
trafficking, ion channel conductance, endocrine function and 
neurotransmission (Wu et al., 2000; Rhee, 2001).  
 
Recently, it was revealed that PLC is normally located in the inner leaflet of 
the plasma membrane, where it can regulate transmembrane proteins, 
including ion channels and transporters (Ma and Eaton, 2005). However, it 
was reported that nuclear phosphoinositides are involved in cell growth and 
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differentiation and it is becoming increasingly clear that in the nucleus 
polyphosphoinositides may act by themselves to influence pre-mRNA splicing 
and chromatin structure (Martelli et al., 2004). 
 
5.2.1 Structure of PLC-β4 
The molecular size of PLC-β isozymes is in the range of 120-150 kDa. The 
amino acid sequences of PLC isozymes are relatively nonconserved with the 
exception of two regions, known as the X and Y domains, which form the 
catalytic core (Rhee et al, 1997). In domain organization, PLC-β4 posses X 
and Y domains in the form of a distorted triose phosphate isomerase (TIM) 
barrel with a highly disordered, charged, and flexible intervening linker region. 
Meanwhile, PLC-β4 posses 4 EF hand domains, and a single C2 domain that 
flank the X and Y catalytic core and presents a long C-terminal extension 
immediately subunits, which may also play a role in nuclear localization. 
 
5.2.2 Activation of PLC-β4 by Gɑq subunits 
PLC-β4 function as effector enzymes for receptors belonging to the rhodopsin 
superfamily of transmembrane proteins that contain seven transmembrane 
spanning (heptahelical) segments (Ji et al, 1998). They are activated by a 
wide range of stimuli, from photons and tiny odorant molecules, to full-sized 
proteins and require specific combinations of Gɑ subunits to couple to their 
effectors. In the standard G protein model of PLC-β4 activation, binding of 
agonist triggers receptor-catalyzed exchange of GTP for bound GDP on the ɑ
-component of the heterotrimer. The GTP-charged subunit then dissociates in 
the plane of the membrane, increasing its catalytic activity and thereby 
amplifying the initial receptor stimulus. 
 
PLC-β4 was first isolated from cerebellum and retina (Min et al, 1993; Jiang et 
al, 1994). Its mRNA is highly concentrated in cerebellar Purkinje and granule 
cells, the median geniculate body, whose axons terminate in the auditory 
cortex, and the lateral geniculate nucleus, where most retinal axons terminate 
 
5. Discussion                                                                     
 
 
64
in a visuotopic representation of each half of the visual field. Because PLC-β4 
is widely distributed on the cell membrane and nucleus and highly 
concentrated in neuron tissues, which composed most of 293FT cells, it 
seems that this may be why PLC-β4 is easily silenced in our experiment. 
 
 
5.3 Possible reasons for low efficiency of RNAi 
In MISSION technical bulletin, it was claimed that each clone set consists of 
3-5 constructs that have been designed against each target gene using a 
proprietary algorithm and therefore, a range of knockdown efficiency, with at 
least one construct from each gene set being > 70%, can be expected when 
using these clones. But In this thesis, from all 26 constructs hairpin 
sequences only one hairpin sequence silenced a target gene. Why is the 
efficiency of RNAi low? Apart from technical reasons, there may be several 
other reasons. 
 
5.3.1 Drawbacks of shRNA 
Paddison et al. (2002) showed that shRNA were somewhat less potent 
silencing triggers than that were siRNAs. siRNAs homologous yielded 
90-95% suppression of gene expression, whereas suppression levels 
achieved with shRNAs ranged from 80-90% on average because of 
mammalian cells contain several endogenous systems that were predicted to 
hamper the application of RNAi. Chief among these is a dsRNA-activated 
protein kinase, PKR, which effects a general suppression of translation via 
phosphorylation of EIF-2α. 
 
The mechanism of action from the shRNA constructs is not well-known. Hall 
et al. (2002) discovered that a shRNA driven by the U6 promoter but with 
strand reversal, such that an accessible anti-sense 3 terminus was not 
available, still remarkably restrain the target gene expression. Therefore, 
these shRNAs might not require primer extended amplification. Maybe gene 
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silencing involving heterochromatin modification which has been found to 
occur with RNAi in fission yeast (Volpe et al., 2002), could be involved. It is 
also of interest that the shRNA constructs that silence gene expression 
effectively in mammalian cells do not contain introns and polyadenylation 
signals. Consequently, they may have to function in the nucleus or are 
efficiently transported to the cytoplasm despite lacking these than ones 
without in plants (Cao et al., 2005), but maybe, for other reasons. 
 
Moreover, McIntyre and Fanning (2006) revealed that shRNA vector 
construction can be disturbed by high mutation rates and ensuing sequencing 
is often problematic. shRNA expression vectors are constructed by one of 
three different methods. The most common method requires the synthesis, 
annealing and ligation of two complementary oligonucleotides into an 
expression vector. The frequency of false positives determined by sequencing 
is high, about 20-40% high (Miyagishi et al, 2004). The unreliability of this 
method is in part due to the difficulty in synthesizing long oligonucleotides (> 
35 bases) and this method requires two long oligonucleotides then the chance 
of mutation is doubled. The second strategy is a PCR approach in which a 
promoter sequence serves as the template. Although it is advantageous that 
only single long oligonucleotides is required, the strong secondary structure 
predicted to form within this primer can lead to the amplification of false 
products (Castanotto et al., 2005). The third method comprises several 
techniques relating to primer extension. Each is based on the principle of a 
polymerase extending the 3 end of overlapping oligonucleotides. 
Nevertheless, this method reduces the cost of oligonucleotides and does not 
need purification but may cause off-set by a high rate of polymerase-induced 
mutations in both the initial extension and repeated cycling steps. In order to 
reduce mutations, conducting all reactions as single-step extensions and 
replacing Taq polymerase with an enzyme better able to counter the 
secondary structure of the hairpin template were adopted. Another reported 
strategy to alleviate sequencing difficulties is to include mismatched bases 
within the shRNA stem (Yu et al., 2003). 
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5.3.2 Target gene-specific characteristics influence 
the RNAi efficiency 
Target gene-specific characteristics such as the accessibility of the 
corresponding target sequences to the RNAi appear to have a significant 
influence on the knockdown efficacy, making certain targets easy or difficult to 
knock down by using siRNA. It has been reported that low-abundant genes 
are less susceptible to siRNA-mediated knockdown (Hu et al., 2004). 
However, recently, Krueger et al. (2007) tested several thousand siRNAs for 
target genes from various gene families and showed that target genes from 
high or moderate to low expression levels were silenced equally well. 
Moreover, it was revealed that the localization of siRNA target sites on the 
transcript and siRNA concentration were not responsible for low silencing 
capacity of siRNA (Krueger et al., 2007). The performance of siRNA showing 
moderate silencing of < 70% knockdown threshold was almost unaffected by 
increasing the siRNA concentration used for transfection, by changing the cell 
type, or by increasing or decreasing the time point of analysis. In this thesis, at 
least 3 clones per gene target were verified and some had 4 shRNA hairpin 
sequences which targeted one gene product respectively, but we failed to 
silence most of the target genes. This may indicate that the level of silencing 
achieved was not exclusively dependent on the siRNA sequences. 
 
In our experiment, because PLC-β4 is widely distributed in neuron tissues and 
293FT cells generated by adenovirus transformation of human embryonic 
kidney cells have many properties of immature neurons, suggesting that the 
adenovirus was taken up and transformed a neuronal lineage cell in the 
original kidney culture (Shaw et al, 2002), PLC-β4 is easy knocked down in 
293FT cells by shRNA. 
 
5.3.3 Limitations of the gene delivery system 
Although chemical gene delivery method with liposomes are most efficacious 
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in all gene delivery systems, this method also has some drawbacks. 
 
5.3.3.1 Mechanism and structure of cationic lipids 
Plasmid-based gene delivery systems utilize various types of synthetic gene 
carriers to condense and protect plasmid DNA (pDNA) from premature 
degradation during storage and transportation from the site of administration 
to the site of gene expression (Mahato, 2005). Gene carriers are also used to 
facilitate endosomal release, while avoiding DNA degradation in the 
lysosomal compartment. Plasmid DNA is condensed into a highly organized 
structure through a complex self-assembly process. Commonly utilized 
synthetic gene carriers are cationic lipids, polymers and peptides that 
condense pDNA by virtue of their electrostatic interactions with the anionic 
phosphate backbone of the nucleic acid chain. 
 
Commercially available cationic lipids used as liposome formulation of alone 
for gene delivery include DOTMA, DOSPA (LipofectAMINE), and DOTAP. 
Most cationic lipids used as transfection reagents have three parts: (1) a 
hydrophobic lipid anchor group; (2) linker group, such as an ester, amide or 
carbamate; and (3) a positively charged head-group, which interacts with 
pDNA, leading to its condensation. 
 
5.3.3.2 Cytotoxicity of cationic lipids 
Despite early excitement, there are serious limitations in the use of most 
existing cationic lipids systems, including high toxicity on repeated use and 
induction of immunostimulation and complement activation. Although 
PEGylation can reduce the levels of compliment activation and binding to 
plasma proteins, transfection efficiencies of PEGylated cationic lipids are 
significantly reduced (Han et al, 2000). 
 
5.3.3.3 Enhanced immunostimulatory activity of nucleic acids 
complexed as lipoplexes 
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Intravenous administration of pentammonio lipid pcTG90:DOPE lipoplexes in 
mice may cause an immune response that prevents a subsequent 
administration of lipoplexes into mice after a relatively short interval (Meyer et 
al, 1999). Repeated systemic gene expression can be achieved upon 
readministration with a minimal time interval of 14 days between two 
injections. When administered 6 days apart, subsequent gene expression is 
inhibited by an initial lipoplex administration containing the pDNA but 
uninhibited when free pDNA was first injected. Expression of the transgene 
was monitored in the serum of animals. 
 
There are several ways by which the immunostimulatory effects of vector 
CpG motifs may be reduced (Schuele, 2000). These include methylation of 
cytosine bases in these motifs, addition of neutralising sequences, elimination 
of CpG motifs, immunosuppression using chemical or biological approaches, 
targeting of vectors away from cells of the reticuloendothelial system, and 
inhibition of endosomal acidification. 
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6. Summary and possible future research 
 
6.1 Summary 
Eight shRNA sets of bacterial glycerol stocks harboring sequence-verified 
shRNA lentiviral plasmid vectors for human genes were employed for 
validation. The aim of this project was to establish knock down of mRNAs in 
human mesenchymal stem cells. Genes to be targeted stem from a project 
that identified candidate genes for controlling transdifferentiation events in 
adipogenic and osteogenic transdifferentiation processes. Using a list of the 
top 40 ranked gene products 8 gene targets were selected for gene silencing. 
Since the viral transfection of MSCs is a time consuming process, genes of 
interest were checked for expression in 293FT cells by RT-PCR. These gene 
products can be silenced in 293FT cells simply by transfection of shRNA 
clones. Bacterial cultures were amplified in LB culture medium from the 
glycerol stocks for use in purification of the shRNA plasmid DNA, which was 
then transfected in 293FT cells by Lipofectamine 2000. Subsequently, after 2, 
4, 6 days of transfection, RT-PCR was performed to authenticate the RNAi 
efficiency. Of all 8 shRNA clone sets, 1 clone silenced the respective target 
gene, PLCB4. Our results indicate that optimal knockdown at the mRNA level 
was reached at 48-96 hours after transfection and the level of silencing 
achieved was not exclusively dependent on the siRNA sequences. Target 
gene-specific characteristics such as the accessibility of the corresponding 
target sequences to the RNAi appear to have a significant influence on the 
knockdown, making certain targets easy or difficult to knock down. 
dsRNA-activated protein kinase, PKR, which effects a general suppression of 
translation via phosphorylation of EIF-2α, and cytotoxicity and enhanced 
immunostimulatory activity of nucleic acids complexed as lipoplexes hamper 
the application of RNAi. According to the MISSION technical bulletin, a range 
of knockdown efficiency, with at least one construct from each gene set being 
>70%, can be expected when using these clones. But In this thesis, from all 
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26 constructs hairpin sequences only one hairpin sequence silenced a target 
gene. 
 
 
6.2 Possible future research 
 
6.2.1 Viral delivery 
Due to their intrinsic mechanism for gene transduction, viruses readily 
function as vectors in a cost-effective and delivery-efficient way. 
 
Lentiviruses, a subclass of retroviruses, have emerged as appealing vectors 
for in vivo application and are widely used for proof of concept experiments. 
While safety concerns still exist, lentiviruses are free of some of the major 
disadvantages hindering use of retroviruses. Namely, there is no risk of 
insertional mutagenesis and lentiviruses are able to efficiently transduce 
primary and non-dividing cells, thereby abolishing two major shortcomings of 
retroviruses for in vivo use. Additionally, lentiviruses can accommodate large 
amounts of data in their genomes, and are less immunogenic than adenoviral 
vectors. 
 
If possible, one could use lentiviral vectors to increase the efficiency of 
transfection and RNAi. 
 
6.2.2 Photoactivatable FPs 
If possible, one could use photoactivatable fluorescent proteins to label the 
PLCB4 or other proteins which are important in the transdifferentiation of 
MSCs between adipocyte and osteoblast differentiation directions in order to 
elucidate the function of proteins and reveal molecular mechanisms
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µg                                                      microgram 
µl                                                       microliter 
µm                                                    micrometer 
Ampr                                          ampicillin resistant 
bp                                                       base pair 
cDNA                                        complementary DNA 
CL                                              cationic liposome 
DMEM                      Dulbeccos modified Eagles medium 
DMSO                                          dimethyl sulfoxide 
DNA                                       deoxyribonucleic acid 
dNTPs                           deoxynucleotide triphosphates 
DOPC                              di-oleoyl phosphatidylcholine 
DOPE                       di-oleoyl phosphatidylethanolamine 
DOSPA           di-oleyloxy spermine-carboxamido 
propanammonium trifluoroacetate 
DOTAP                   di-oleoyl trimethylammonium propane 
dsRBD                           dsRNA binding domain proteins 
dsRNA                                         double strand RNA 
EB                                             ethidium bromide 
EDTA                          ethylene diamine tetraacetic acid 
FACS                         fluorescence activated cell sorting 
FBS                                            fetal bovine serum 
FCS                       flurescence correlation spectroscopy 
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FLIP                        fluorescence loss in photobleaching 
FRET                   fluorescence resonance energy transfer 
FRAP               fluorescence recovery after photobleaching 
GFP                                    green fluorescent protein 
HPLC-H2O     High Performance Liquid Chromatography water 
HEK cells                        Human Embryonic Kidney cells 
LB                                           Luria-Betani medium 
MDB                                  Membrane Desalting Buffer 
MEM                                 minimum essential medium 
mg                                                      milligram 
mm                                                     millimeter 
mM                                                     millimolar 
miRNA                                    micro-ribonucleic acid 
miRNP                                micro-robonucleic protein 
mRNA                               messenger ribonucleic acid 
MSCs                                   mesenchymal stem cells 
NEAA                                  non-essential amino acids 
ng                                                      nanogram 
nt                                                      nucleotide 
OD                                                 optical density 
PBS                                   phosphate-buffered saline 
PCR                                   polymerase chain reaction 
PEI                                            polyethyleneimine 
RNA                                              ribonucleic acid 
RNAase                                             ribonuclease 
rpm                                             round per minute 
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RT                     room temperature; reverse transcription 
RT-PCR                                reverse transcription PCR 
saRNA                                      small activating RNA 
SDS                                       sodium dodecyl sulfate 
siRNA                                      small interfering RNA 
RISC                            RNA-induced silencing complex 
RNAi                                            RNA interference 
TBE                                  Tris-Boric acid, EDTA buffer 
TE                                                 Tris-HCl, EDTA 
Tris                         Tris (hydroxymethyl) aminomethane 
TSR                              Template Suppression Reagent 
UV                                                      ultraviolet 
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